Loading Events

Upcoming Events

Events Search and Views Navigation

Event Views Navigation

  • There were no results found.

“I do enjoy these meetings which are extremely informative and what I find most stimulating is the focus on future research.  You are to be congratulated for organising these meetings and I am delighted to take part”

“What a crew! This sounds GREAT!

I really enjoyed the discussions and the whole format of the day
It was the most exciting and thought-provoking meeting that I have ever attended
Thanks for allowing me to attend the Symposium on rectal cancer, which was really outstanding in underscoring the many needs we have in this field. I enjoyed it very much

“Sounds fantastic”
“Inspiring talks and very interesting discussions, great meeting”
Thank you for such an outstanding meeting.. One of the best – a very inspiring day!
“I know how good these meetings are”
Thank you for the symposium yesterday.  I returned on the train last night with renewed enthusiasm and a desire to try and improve our service.
“I am sure that it will be as entertaining and thought provoking as ever”

Colorectal Cancer Imaging Multidisciplinary Research Group

Publications

2021

Hodges, N., Mackenzie, H., D’Souza, N., Brown, G., & Miskovic, D. (2021). Survival outcomes for right-versus left-sided colon cancer and rectal cancer in England: A propensity-score matched population-based cohort study.. Eur J Surg Oncol. doi:/j.ejso.2021.10.007

Tan, J. J., V. Carten, R., Babiker, A., Abulafi, M., Lord, A. C., & Brown, G. (2021). Prognostic Importance of MRI-Detected Extramural Venous Invasion in Rectal Cancer: A Literature Review and Systematic Meta-Analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 111(2), 385-394. doi:/j.ijrobp.2021.05.136

Robb, H. D., Scrimgeour, G., Boshier, P. R., Balyasnikova, S., Brown, G., Bello, F., & Kontovounisios, C. (2021). Current and possible future role of 3D modelling within oesophagogastric surgery: a scoping review protocol. BMJ OPEN, 11(10), 4 pages. doi:10.1136/bmjopen-2020-045546

Brouwer, N. P. M., Lord, A. C., Terlizzo, M., Bateman, A. C., West, N. P., Goldin, R., . . . Brown, G. (2021). Interobserver variation in the classification of tumor deposits in rectal cancer-is the use of histopathological characteristics the way to go?. VIRCHOWS ARCHIV, 8 pages. doi:10.1007/s00428-021-03197-0

Rao, S., Guren, M. G., Khan, K., Brown, G., Renehan, A. G., Steigen, S. E., . . . Arnold, D. (2021). Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 32(9), 1087-1100. doi:10.1016/j.annonc.2021.06.015

Day, N., D’Souza, N., Shaw, A., Lord, A., Abulafi, M., Moran, B., . . . Brown, G. (2021). Local recurrence in sigmoid cancer is a hidden problem, could CT prognostic factors be of value in their prevention? A multi-centre study of 414 patients.. Eur J Surg Oncol, 47(8), 2093-2099. doi:10.1016/j.ejso.2021.03.254

Lord, A., Brown, G., Abulafi, M., Bateman, A., Frankel, W., Goldin, R., . . . Nagtegaal, I. (2021). Histopathological diagnosis of tumour deposits in colorectal cancer: a Delphi consensus study. HISTOPATHOLOGY, 79(2), 168-175. doi:10.1111/his.14344

Rokan, Z., Simillis, C., Kontovounisios, C., Moran, B. J., Tekkis, P., & Brown, G. (2021). Systematic review of classification systems for locally recurrent rectal cancer. BJS OPEN, 5(3), 14 pages. doi:10.1093/bjsopen/zrab024

2020

Huddy, J. R., Tilney, H. S., Rasheed, S., Rasheed, S., Tilney, H. S., & Brown, G. (2020). Comment on “Cancer Surgery During COVID-19: How we Move Forward”.. Ann Surg. doi:10.1097/SLA.0000000000004544

Lord, A. C., DʼSouza, N., Shaw, A., Rokan, Z., Moran, B., Abulafi, M., . . . Brown, G. (2020). MRI-Diagnosed Tumour Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer.. Ann Surg. doi:10.1097/SLA.0000000000004499

Huddy, J. R., Rasheed, S., Brown, G., & Tilney, H. S. (2020). Letter to the Editor RE: “COVID-19 Impact on Colorectal Daily Practice-How Long Will It Take to Catch Up?”. JOURNAL OF GASTROINTESTINAL SURGERY, 24(11), 2696-2697. doi:10.1007/s11605-020-04795-0

D’Souza, N., Lord, A., Shaw, A., Patel, A., Balyasnikova, S., Tudyka, V., . . . Brown, G. (2020). The sigmoid take-off: An anatomical imaging definition of the rectum validated on specimen analysis. EJSO, 46(9), 1668-1672. doi:10.1016/j.ejso.2020.01.008

Keller, D. S., Berho, M., Brown, G., Hull, T., Moeslein, G., & Wexner, S. D. (2020). A narrative celebrating the recent contributions of women to colorectal surgery. SURGERY, 168(3), 355-362. doi:10.1016/j.surg.2020.06.024

Lord, A. C., Knijn, N., Brown, G., & Nagtegaal, I. D. (2020). Pathways of spread in rectal cancer: a reappraisal of the true routes to distant metastatic disease. EUROPEAN JOURNAL OF CANCER, 128, 1-6. doi:10.1016/j.ejca.2019.12.025

Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rodel, C., Cervantes, A., & Arnold, D. (2017). Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 28, 22-40. doi:10.1093/annonc/mdx224

Khakoo, S., Carter, P. D., Brown, G., Valeri, N., Picchia, S., Bali, M. A., . . . Cunningham, D. (2020). MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. CLINICAL CANCER RESEARCH, 26(1), 183-192. doi:10.1158/1078-0432.CCR-19-1996

Lord, A. C., Moran, B., Abulafi, M., Rasheed, S., Nagtegaal, I. D., Terlizzo, M., & Brown, G. (2020). Can extranodal tumour deposits be diagnosed on MRI? Protocol for a multicentre clinical trial (the COMET trial). BMJ OPEN, 10(10), 7 pages. doi:10.1136/bmjopen-2019-033395

Sclafani, F., Wilson, S. H., Cunningham, D., De Castro, D. G., Kalaitzaki, E., Begum, R., . . . Chau, I. (2020). Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. INTERNATIONAL JOURNAL OF CANCER, 146(1), 94-102. doi:10.1002/ijc.32507

2019

D’Souza, N., Babberich, M. P. M. D. N. T., d’Hoore, A., Tiret, E., Xynos, E., Beets-Tan, R. G. H., . . . Brown, G. (2019). Definition of the Rectum An International, Expert-based Delphi Consensus. ANNALS OF SURGERY, 270(6), 955-959. doi:10.1097/SLA.0000000000003251

D’Souza, N., Shaw, A., Lord, A., Balyasnikova, S., Abulafi, M., Tekkis, P., & Brown, G. (2019). Assessment of a Staging System for Sigmoid Colon Cancer Based on Tumor Deposits and Extramural Venous Invasion on Computed Tomography. JAMA NETWORK OPEN, 2(12), 11 pages. doi:10.1001/jamanetworkopen.2019.16987

Lord, A. C., Martinez, C. G., D’Souza, N., Pucher, P. H., Brown, G., & Nagtegaal, I. D. (2019). The significance of tumour deposits in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis. EUROPEAN JOURNAL OF CANCER, 122, 1-8. doi:10.1016/j.ejca.2019.08.020

Davidson, M., Aronson, L. I., Howard-Reeves, J., Bryant, H., Cutts, R. J., Hulkki-Wilson, S., . . . Chong, I. Y. (2019). Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. EUROPEAN JOURNAL OF CANCER, 122, 12-21. doi:10.1016/j.ejca.2019.09.003

D’Souza, N., Lord, A. C., Shaw, A., Patel, A., Balyasnikova, S., Tudyka, V., . . . Brown, G. (2019). Ex vivo specimen MRI and pathology confirm a rectosigmoid mesenteric waist at the junction of the mesorectum and mesocolon. COLORECTAL DISEASE, 22(2), 212-218. doi:10.1111/codi.14856

Lord, A., D’Souza, N., Shaw, A., Day, N., & Brown, G. (2019). The Current Status of Nodal Staging in Rectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 15(5), 143-148. doi:10.1007/s11888-019-00441-3

Vallance, A. E., Harji, D., & Fearnhead, N. S. (2019). Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. EJSO, 45(9), 1567-1574. doi:10.1016/j.ejso.2019.04.005

Kennedy, E. D., Simunovic, M., Jhaveri, K., Kirsch, R., Brierley, J., Drolet, S., . . . Baxter, N. N. (2019). Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery The Phase 2 Nonrandomized QuickSilver Clinical Trial. JAMA ONCOLOGY, 5(7), 961-966. doi:10.1001/jamaoncol.2019.0186

Keller, D. S., & Brown, G. (2019). Invited editorial re: “Response assessment after (chemo) radiotherapy for rectal cancer: Why are we missing complete responses with MRI and endoscopy?”. EJSO, 45(6), 929-930. doi:10.1016/j.ejso.2018.12.013

West, M. A., Astin, R., Moyses, H. E., Cave, J., White, D., Levett, D. Z. H., . . . Jack, S. (2019). Exercise prehabilitation may lead to augmented tumor regression following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. ACTA ONCOLOGICA, 58(5), 588-595. doi:10.1080/0284186X.2019.1566775

Pooni, A., Al-Sukhni, E., Milot, L., Fruitman, M., Victor, J. C., Schmocker, S., . . . Kennedy, E. (2019). Selection of Patients With Rectal Cancer for Preoperative Chemoradiotherapy: Are T Category and Nodal Status All That Matters?. DISEASES OF THE COLON & RECTUM, 62(4), 447-453. doi:10.1097/DCR.0000000000001229

D’Souza, N., Lord, A., Shaw, A., Abulafi, M., Kontovounisios, C., Sjovall, A., . . . Brown, G. (2019). Meta-analysis of oncological outcomes of sigmoid cancers: A hidden epidemic of R1 “palliative” resections. EJSO, 45(4), 489-497. doi:10.1016/j.ejso.2018.09.028

Balyasnikova, S., & Brown, G. (2019). The MRI assessment of SPECC (significant polyps and early colorectal cancer) lesions.. Colorectal Dis, 21 Suppl 1, 19-22. doi:10.1111/codi.14526

West, M. A., Astin, R., Moyses, H. E., Cave, J., White, D., Levett, D. Z. H., . . . Jack, S. (2019). Exercise prehabilitation may lead to augmented tumor regression following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.. Acta Oncol, 1-8. doi:10.1080/0284186X.2019.1566775

2018

Sclafani, F., Kalaitzaki, E., Cunningham, D., Tait, D., Brown, G., & Chau, I. (2018). Neoadjuvant rectal score: run with the hare and hunt with the hounds. ANNALS OF ONCOLOGY, 29(11), 2261-2262. doi:10.1093/annonc/mdy403

Siddiqui, M. R. S., Simillis, C., Bhoday, J., Battersby, N. J., Mok, J., Rasheed, S., . . . Brown, G. (2018). A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. EUROPEAN JOURNAL OF CANCER, 104, 47-61. doi:10.1016/j.ejca.2018.07.131

D’Souza, N., Lord, A., Shaw, A., Abulafi, M., Kontovounisios, C., Sjövall, A., . . . Brown, G. (2018). Meta-analysis of oncological outcomes of sigmoid cancers: A hidden epidemic of R1 “palliative” resections.. Eur J Surg Oncol. doi:10.1016/j.ejso.2018.09.028

Patel, A., Rockall, A., Guthrie, A., Gleeson, F., Worthy, S., Grubnic, S., . . . Brown, G. (2018). Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. BMJ OPEN, 8(10), 11 pages. doi:10.1136/bmjopen-2017-018499

Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., . . . ESMO Guidelines Committee. (2018). Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.. Ann Oncol, 29(Supplement_4), iv263. doi:10.1093/annonc/mdy161

Davidson, M., Nankivell, M., Cunningham, D., Starling, N., Koh, D. -M., Brown, G., . . . Riddell, A. (2018). Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy. In ANNALS OF ONCOLOGY Vol. 29 (pp. 1 page). Munich, GERMANY: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277301217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Khakoo, S., Carter, P., Valeri, N., Shaikh, R., Jones, T., Begum, R., . . . Cunningham, D. (2018). Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer. In ANNALS OF ONCOLOGY Vol. 29 (pp. 661). Munich, GERMANY: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277304231&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Lord, A. C., D’Souza, N., Pucher, P. H., Moran, B. J., Abulafi, A. M., Wotherspoon, A., . . . Brown, G. (2018). Author response to comment on ‘significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis’. EUROPEAN JOURNAL OF CANCER, 105, 129-130. doi:10.1016/j.ejca.2018.08.018

D’Souza, N., Balyasnikova, S., Tudyka, V., Lord, A., Shaw, A., Abulafi, M., . . . Brown, G. (2018). Variation in landmarks for the rectum: an MRI study. COLORECTAL DISEASE, 20(10), O304-O309. doi:10.1111/codi.14398

D’Souza, N., Babberich, M. P. M. D. N. T., Lord, A., Shaw, A., Abulafi, M., Tekkis, P., . . . Brown, G. (2018). The rectosigmoid problem. SURGICAL ONCOLOGY-OXFORD, 27(3), 521-525. doi:10.1016/j.suronc.2018.06.005

Chand, M., Keller, D. S., Mirnezami, R., Bullock, M., Bhangu, A., Moran, B., . . . Berho, M. (2018). Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 10(7), 145-158. doi:10.4251/wjgo.v10.i7.145

Tekkis, P., Tait, D., Cunningham, D., & Brown, G. (2018). Is organ preservation in rectal cancer ready for prime time?. LANCET, 391(10139), 2480-2482. doi:10.1016/S0140-6736(18)31324-2

Sao Juliao, G. P., Ortega, C. D., Vailati, B. B., Coutinho, F. A. B., Rossi, G., Habr-Gama, A., . . . Perez, R. O. (2018). The Estimate of the Impact of Coccyx Resection in Surgical Field Exposure During Abdominal Perineal Resection Using Preoperative High-Resolution Magnetic Resonance. WORLD JOURNAL OF SURGERY, 42(11), 3765-3770. doi:10.1007/s00268-018-4683-x

Bhoday, J., Glimelius, B., Tait, D., Glynne-Jones, R., Adams, R., & Brown, G. (2018). Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. COLORECTAL DISEASE, 20, 97-99. doi:10.1111/codi.14088

Battersby, N. J., Perez, R. O., Baxter, N., Moran, B., & Brown, G. (2018). Session 4: Trying to augment response with chemotherapy: a triumph of hope over experience?. COLORECTAL DISEASE, 20, 100-102. doi:10.1111/codi.14089

Dattani, M., Marijnen, C., Moran, B., Tait, D., Cunningham, C., Rodriguez-Bigas, M., & Brown, G. (2018). Session 4: Shaping radiotherapy for rectal cancer: should this be personalized?. COLORECTAL DISEASE, 20, 92-96. doi:10.1111/codi.14087

Read, J., Tekkis, P., Rullier, E., Nicholls, J., Mortensen, N., Marks, J., . . . Brown, G. (2018). Session 3: Many ways to organ preserve the rectum but which is correct?. COLORECTAL DISEASE, 20, 82-87. doi:10.1111/codi.14085

Patel, A., Chang, G., Wale, A., Chong, I., Rutten, H., Nicholls, J., . . . Brown, G. (2018). Session 3: Intra-operative radiotherapy – creating new surgical boundaries. COLORECTAL DISEASE, 20, 65-75. doi:10.1111/codi.14083

Balyasnikova, S., Vuong, T., Wale, A., Chong, I., Rutten, H., & Brown, G. (2018). Session 3: Boosting primary and recurrent rectal cancer: how far can we push the radiotherapy envelope?. COLORECTAL DISEASE, 20, 88-91. doi:10.1111/codi.14086

Patel, U. B., Blomqvist, L., Chau, I., Nicholls, J., & Brown, G. (2018). Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response. COLORECTAL DISEASE, 20, 76-81. doi:10.1111/codi.14084

Patel, A., Holm, T., Wale, A., Rutten, H., Nicholls, J., Hawkins, M., . . . Brown, G. (2018). Session 3: Beyond the boundaries of Total Mesorectal Excision – where surgeons fear to tread. COLORECTAL DISEASE, 20, 61-64. doi:10.1111/codi.14082

Siddiqui, M., Nagtegaal, I., Santiago, I., Knijn, N., Berho, M., Mirnezami, A., . . . Brown, G. (2018). Session 2: What causes liver metastases – lymph nodes or is it something else?. COLORECTAL DISEASE, 20, 39-42. doi:10.1111/codi.14077

Wale, A., Van Cutsem, E., Rao, S., Cunningham, D., & Brown, G. (2018). Session 2: Synchronous metastatic disease-liver first or primary first? The oncologist decides. COLORECTAL DISEASE, 20, 52-55. doi:10.1111/codi.14080

Siddiqui, M., Chand, M., Eng, C., Mehdizadeh, A., Mirnezami, A., & Brown, G. (2018). Session 2: Mutational discordance: the big challenge in personalized treatments – any solutions?. COLORECTAL DISEASE, 20, 49-51. doi:10.1111/codi.14079

Balyasnikova, S., Haboubi, N., Wale, A., Santiago, I., Morgan, M., Cunningham, D., . . . Brown, G. (2018). Session 2: Extramural vascular invasion and extranodal deposits: should they be treated the same?. COLORECTAL DISEASE, 20, 43-48. doi:10.1111/codi.14078

Patel, U. B., Cervantes, A., Fernandez-Martos, C., Sclafani, F., Cunningham, D., Nilsson, P., & Brown, G. (2018). Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?. COLORECTAL DISEASE, 20, 56-60. doi:10.1111/codi.14081

Bhoday, J., Martling, A., Strassburg, J., & Brown, G. (2018). Session 1: The surgeon as a prognostic factor in colon and rectal cancer?. COLORECTAL DISEASE, 20, 36-38. doi:10.1111/codi.14076

Wale, A., Wexner, S. D., Saur, N. M., Massarotti, H., Laurberg, S., Kennedy, E., . . . Brown, G. (2018). Session 1: The evolution and development of the multidisciplinary team approach: USA, European and UK experiences – what can we do better?. COLORECTAL DISEASE, 20, 17-27. doi:10.1111/codi.14073

Tudyka, V., Madoff, R., Wale, A., Laurberg, S., Yano, H., & Brown, G. (2018). Session 1: Colon cancer-10years behind the rectum. COLORECTAL DISEASE, 20, 28-33. doi:10.1111/codi.14074

Brown, G. (2018). Proceedings of the Future Horizons International Experts Meeting in Colorectal Cancer Held in London on 25th June 2015. Edited by: Dr Anita Wale and Prof Gina Brown. COLORECTAL DISEASE, 20, 5-7. doi:10.1111/codi.14068

Bernier, L., Balyasnikova, S., Tait, D., & Brown, G. (2018). Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 14(2), 37-55. doi:10.1007/s11888-018-0398-5

Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., . . . Valeri, N. (2018). KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. SCIENTIFIC REPORTS, 8, 9 pages. doi:10.1038/s41598-018-19212-5

Chand, M., & Brown, G. (2018). Important imaging considerations in the pre-operative assessment of rectal cancer (Reprinted from Seminars in Colon and Rectal Surgery, vol 25, pg 6-12, 2014). SEMINARS IN COLON AND RECTAL SURGERY, 29(4), 199-205. doi:10.1053/j.scrs.2018.11.008

Lawler, M., Alsina, D., Adams, R. A., Anderson, A. S., Brown, G., Fearnhead, N. S., . . . Tomlinson, I. (2018). Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. GUT, 67(1), 179-193. doi:10.1136/gutjnl-2017-315333

Siddiqui, M., Balyansikova, S., Nagtegaal, I., West, N., Murray, G., Bosch, S., . . . Brown, G. (2018). Agreement between histopathologic regression and MRI Tumour Regression (mrTRG) scales used to assess response for rectal cancers. International Journal of Surgery. doi:10.1016/j.ijsu.2018.05.190

2017

Battersby, N. J., Moran, B., Stelzner, S., West, N. P., Branagan, G., Strassburg, J., . . . Brown, G. (2017). Reply to: Does MRI Restaging of Rectal Cancer After Chemoradiotherapy Actually Permit a Change in Surgical Management?. ANNALS OF SURGERY, 266(6), E116-E118. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000419022400092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Mendes, L. S. T., Balyasnikova, S., . . . Chau, I. (2017). Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. BRITISH JOURNAL OF CANCER, 117(10), 1478-1485. doi:10.1038/bjc.2017.320

Bhoday, J., Balyasnikova, S., Wale, A., & Brown, G. (2017). How Should Imaging Direct/Orient Management of Rectal Cancer?. CLINICS IN COLON AND RECTAL SURGERY, 30(5), 297-312. doi:10.1055/s-0037-1606107

Siddiqui, M. R. S., Shanmuganandan, A. P., Rasheed, S., Tekkis, P., Brown, G., & Abulafi, A. M. (2017). An audit comparing the reporting of staging MRI scans for rectal cancer with the London Cancer Alliance (LCA) guidelines. EJSO, 43(11), 2093-2104. doi:10.1016/j.ejso.2017.09.003

Lord, A. C., D’Souza, N., Pucher, P. H., Moran, B. J., Abulafi, A. M., Wotherspoon, A., . . . Brown, G. (2017). Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis. EUROPEAN JOURNAL OF CANCER, 82, 92-102. doi:10.1016/j.ejca.2017.05.027

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Mendes, L. S. T., Evans, J., . . . Chau, I. (2017). Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC). In ANNALS OF ONCOLOGY Vol. 28 (pp. 2 pages). Madrid, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324004275&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Battersby, N. J., Dattani, M., Rao, S., Cunningham, D., Tait, D., Adams, R., . . . Brown, G. (2017). A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. TRIALS, 18, 14 pages. doi:10.1186/s13063-017-2085-2

Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rodel, C., Cervantes, A., & Arnold, D. (2017). Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 28, 22-40. doi:10.1093/annonc/mdx224

Balyasnikova, S., Read, J., Wotherspoon, A., Rasheed, S., Tekkis, P., Tait, D., . . . Brown, G. (2017). Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer. BMJ OPEN GASTROENTEROLOGY, 4(1), 9 pages. doi:10.1136/bmjgast-2017-000151

Sclafani, F., Brown, G., Cunningham, D., Rao, S., Tekkis, P., Tait, D., . . . Chau, I. (2017). Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. ONCOLOGIST, 22(6), 728-736. doi:10.1634/theoncologist.2016-0396

Siddiqui, M. R. S., Simillis, C., Hunter, C., Chand, M., Bhoday, J., Garant, A., . . . Brown, G. (2017). A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. BRITISH JOURNAL OF CANCER, 116(12), 1513-1519. doi:10.1038/bjc.2017.99

Sugarbaker, P. H., Sardi, A., Brown, G., Dromain, C., Rousset, P., & Jelinek, J. S. (2017). Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 33(5), 497-504. doi:10.1080/02656736.2017.1317368

Patel, U. B., Brown, G., Machado, I., Santos-Cores, J., Pericay, C., Ballesteros, E., . . . Fernandez-Martos, C. (2017). MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. ANNALS OF ONCOLOGY, 28(2), 344-353. doi:10.1093/annonc/mdw616

Sclafani, F., Brown, G., Cunningham, D., Rao, S., Tekkis, P. P., & Tait, D. M. (2017). Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443281700690&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Hunter, C., Siddiqui, M., Delisle, T. G., Blake, H., Jeyadevan, N., Abulafi, M., . . . Brown, G. (2017). CT and 3-T MRI accurately identify T3c disease in colon cancer, which strongly predicts disease-free survival. CLINICAL RADIOLOGY, 72(4), 307-315. doi:10.1016/j.crad.2016.11.014

Georgiou, P. A., Ali, S. M., Brown, G., Rasheed, S., & Tekkis, P. P. (2017). Extended lymphadenectomy for locally advanced and recurrent rectal cancer. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 32(3), 333-340. doi:10.1007/s00384-016-2711-6

Ciombor, K. K., Ernst, R. D., & Brown, G. (2017). Diagnosis and Diagnostic Imaging of Anal Canal Cancer. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 26(1), 45-+. doi:10.1016/j.soc.2016.07.002

Balyasnikova, S., Haboubi, N., Moran, B., & Brown, G. (2017). Histopathological and radiological reporting in rectal cancer: concepts and controversies, facts and fantasies. TECHNIQUES IN COLOPROCTOLOGY, 21(1), 15-23. doi:10.1007/s10151-016-1555-y

Battersby, N. J., Moran, B., Stelzner, S., West, N. P., Branagan, G., Strassburg, J., . . . Brown, G. (2017). Reply to: Does MRI Restaging of Rectal Cancer After Chemoradiotherapy Actually Permit a Change in Surgical Management?. Ann Surg, 266(6), e116-e118. doi:10.1097/SLA.0000000000001791

Simillis, C., Baird, D. L. H., Kontovounisios, C., Pawa, N., Brown, G., Rasheed, S., & Tekkis, P. P. (2017). A Systematic Review to Assess Resection Margin Status After Abdominoperineal Excision and Pelvic Exenteration for Rectal Cancer. ANNALS OF SURGERY, 265(2), 291-299. doi:10.1097/SLA.0000000000001963

Balyasnikova, S., Read, J., Tait, D., Wotherspoon, A., Swift, I., Cunningham, D., . . . Brown, G. (2017). The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. COLORECTAL DISEASE, 19(2), 139-147. doi:10.1111/codi.13477

2016

Harris, D. A., Thorne, K., Hutchings, H., Islam, S., Holland, G., Hatcher, O., . . . Beynon, J. (2016). Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR). BMJ OPEN, 6(11), 8 pages. doi:10.1136/bmjopen-2016-012496

Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., . . . Reynolds, A. R. (2016). Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. NATURE MEDICINE, 22(11), 1294-1302. doi:10.1038/nm.4197

Evans, J., Bhoday, J., Sizer, B., Tekkis, P., Swift, R., Perez, R., . . . Brown, G. (2016). Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?. ANNALS OF ONCOLOGY, 27, 1 page. doi:10.1093/annonc/mdw370.1

Sclafani, F., Chau, I., Cunningham, D., Vlachogiannis, G., Eltahir, Z., Lampis, A., . . . Valeri, N. (2016). KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial. ANNALS OF ONCOLOGY, 27, 1 page. doi:10.1093/annonc/mdw370.73

O’Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., . . . Waterton, J. C. (2017). Imaging biomarker roadmap for cancer studies. NATURE REVIEWS CLINICAL ONCOLOGY, 14(3), 169-186. doi:10.1038/nrclinonc.2016.162

Siddiqui, M. R. S., Bhoday, J., Battersby, N. J., Chand, M., West, N. P., Abulafi, A. -M., . . . Brown, G. (2016). Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. WORLD JOURNAL OF GASTROENTEROLOGY, 22(37), 8414-8434. doi:10.3748/wjg.v22.i37.8414

Lutz, M. P., Zalcberg, J. R., Glynne-Jones, R., Ruers, T., Ducreux, M., Arnold, D., . . . Otto, F. (2016). Corrigendum to “2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer” [Eur J Cancer 63 (August 2016) 11-24].. Eur J Cancer, 68, 208-209. doi:10.1016/j.ejca.2016.08.017

Battersby, N. J., How, P., Moran, B. J., Stelzner, S., West, N. P., Branagan, G., . . . Pedersen, B. G. (2016). The MERCURY II Study: Prospective Validation of a Low Rectal Cancer Assessment System Using Magnetic Resonance Imaging, and Development of a Local Recurrence Risk Stratification Model. In JOURNAL OF PATHOLOGY Vol. 240 (pp. 18). Univ Nottingham, Sch Med, Acad Univ Mol Pathol Div Canc & Stem Cells, Nottingham, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000386691900075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhoday, J., Smith, F., Siddiqui, M. R., Balyasnikova, S., Swift, R. I., Perez, R., . . . Brown, G. (2016). Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy. DISEASES OF THE COLON & RECTUM, 59(10), 925-933. doi:10.1097/DCR.0000000000000667

Chand, M., Rasheed, S., Heald, R., Swift, I., West, N., Rao, S., . . . Brown, G. (2017). Adjuvant chemotherapy may improve disease-free survival in patients with rectal cancer positive for MRI-detected extramural venous invasion following chemoradiation. COLORECTAL DISEASE, 19(6), 537-543. doi:10.1111/codi.13535

Kontovounisios, C., Tan, E., Pawa, N., Brown, G., Tait, D., Cunningham, D., . . . Tekkis, P. (2017). The selection process can improve the outcome in locally advanced and recurrent colorectal cancer: activity and results of a dedicated multidisciplinary colorectal cancer centre. COLORECTAL DISEASE, 19(4), 331-338. doi:10.1111/codi.13517

Siddiqui, M. R. S., Gormly, K. L., Bhoday, J., Balyansikova, S., Battersby, N. J., Chand, M., . . . Brown, G. (2016). Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). CLINICAL RADIOLOGY, 71(9), 854-862. doi:10.1016/j.crad.2016.05.005

Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., . . . Turner, N. C. (2016). High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. CANCER DISCOVERY, 6(8), 838-851. doi:10.1158/2159-8290.CD-15-1246

Sclafani, F., Chau, I., Cunningham, D., Lampis, A., Hahne, J. C., Ghidini, M., . . . Valeri, N. (2016). Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. CARCINOGENESIS, 37(9), 852-857. doi:10.1093/carcin/bgw073

Hunter, C., Blake, H., Jeyadevan, N., Abulafi, M., Swift, I., Toomey, P., & Brown, G. (2016). Local staging and assessment of colon cancer with 1.5-T magnetic resonance imaging. BRITISH JOURNAL OF RADIOLOGY, 89(1064), 9 pages. doi:10.1259/bjr.20160257

Balyasnikova, S., & Brown, G. (2016). Optimal Imaging Strategies for Rectal Cancer Staging and Ongoing Management. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 17(6), 11 pages. doi:10.1007/s11864-016-0403-7

Lutz, M. P., Zalcberg, J. R., Glynne-Jones, R., Ruers, T., Ducreux, M., Arnold, D., . . . Otto, F. (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. EUROPEAN JOURNAL OF CANCER, 63, 11-24. doi:10.1016/j.ejca.2016.04.010

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Tait, D., Peckitt, C., . . . Chau, I. (2016). PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. ANNALS OF ONCOLOGY, 27(8), 1557-1565. doi:10.1093/annonc/mdw215

Hunter, C., & Brown, G. (2016). Pre-operative staging of rectal cancer: a review of imaging techniques. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 10(9), 1011-1025. doi:10.1080/17474124.2016.1179577

Battersby, N. J., How, P., Moran, B., Stelzner, S., West, N. P., Branagan, G., . . . Brown, G. (2016). Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. ANNALS OF SURGERY, 263(4), 751-760. doi:10.1097/SLA.0000000000001193

Balyasnikova, S., & Brown, G. (2016). Imaging Advances in Colorectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 12(3), 162-169. doi:10.1007/s11888-016-0321-x

West, M. A., Dimitrov, B. D., Moyses, H. E., Kemp, G. J., Loughney, L., White, D., . . . Brown, G. (2016). Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer – A comparison of magnetic resonance imaging at two time points and histopathological responses. EJSO, 42(9), 1350-1358. doi:10.1016/j.ejso.2016.04.003

Sclafani, F., & Brown, G. (2016). Extramural Venous Invasion (EMVI) and Tumour Regression Grading (TRG) as Potential Prognostic Factors for Risk Stratification and Treatment Decision in Rectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 12(3), 130-140. doi:10.1007/s11888-016-0319-4

Siddiqui, M. R. S., Balyansikova, S., Bhoday, J., Chand, M., Rao, S., Tekkis, P., . . . Brown, G. (2016). MRI assessment of intraluminal and extramural regression after chemoradiation therapy. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 18). Royal Coll Surg England, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374301300046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Siddiqui, M. R. S., Bhoday, J., Balyansikova, S., Battersby, N. J., Gormly, K. L., Rao, S., . . . Brown, G. (2016). Inter-observer agreement of radiologists assessing the response of rectal cancers after chemoradiation therapy according to MRI tumour regression grading (mrTRG). In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 17). Royal Coll Surg England, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374301300043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Siddiqui, M. R. S., Chand, M., Bhoday, J., Tekkis, P., Abulafi, A. M., & Brown, G. (2016). Correlation between MRI detected extra-mural vascular invasion (mrEMVI) in rectal cancer and metastatic disease: a meta-analysis. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 19). Royal Coll Surg England, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374301300049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Hill, E. J., Roberts, C., Franklin, J. M., Enescu, M., West, N., MacGregor, T. P., . . . Sharma, R. A. (2016). Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. CLINICAL CANCER RESEARCH, 22(8), 1922-1931. doi:10.1158/1078-0432.CCR-15-1489

Smyth, E. C., Turner, N. C., Pearson, A., Peckitt, C., Chau, I., Watkins, D. J., . . . Cunningham, D. (2016). Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2016.34.4_suppl.154

Chand, M., Siddiqui, M. R. S., Swift, I., & Brown, G. (2016). Systematic review of prognostic importance of extramural venous invasion in rectal cancer. WORLD JOURNAL OF GASTROENTEROLOGY, 22(4), 1721-1726. doi:10.3748/wjg.v22.i4.1721

2015

Smyth, E. C., Turner, N., Pearson, A., Peckitt, C., Chau, I., Watkins, D., . . . Cunningham, D. (2015). Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results. In ANNALS OF ONCOLOGY Vol. 26 (pp. 44). Singapore, SINGAPORE: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367158700145&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Tekkis, P., Tan, E., Kontovounisios, C., Kinross, J., Georgiou, C., Nicholls, R. J., . . . Brown, G. (2015). Hand-sewn coloanal anastomosis for low rectal cancer: technique and long-term outcome. COLORECTAL DISEASE, 17(12), 1062-1070. doi:10.1111/codi.13028

Machado, I., Patel, U., Brown, G., Salud, A., Gil, M., Montagut, C., . . . Fernandez-Martos, C. (2015). The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S387). Vienna, AUSTRIA: ELSEVIER SCI LTD. doi:10.1016/S0959-8049(16)31082-6

Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., . . . Valeri, N. (2015). Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S396). Vienna, AUSTRIA: ELSEVIER SCI LTD. doi:10.1016/S0959-8049(16)31107-8

West, M. A., Grocott, M. P. W., Jack, S., Kemp, G. J., & Brown, G. (2015). Exercise training response is associated with greater tumour regression in rectal cancer following neoadjuvant chemoradiotherapy. In BRITISH JOURNAL OF SURGERY Vol. 102 (pp. 55). Manchester, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368130400175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Hugen, N., Brown, G., Glynne-Jones, R., de Wilt, J. H. W., & Nagtegaal, I. D. (2016). Advances in the care of patients with mucinous colorectal cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 13(6), 361-369. doi:10.1038/nrclinonc.2015.140

Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., . . . Valeri, N. (2015). Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. ANNALS OF ONCOLOGY, 26(9), 1936-1941. doi:10.1093/annonc/mdv285

Gollins, S., Sebag-Montefiore, D., Adams, R., Saunders, M. P., Grieve, R., Scott, N., . . . Hurt, C. (2015). A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC) with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative radiotherapy (SCPRT) then immediate surgery in operable rectal cancer (ORC): COPERNICUS (NCT01263171). In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036900828&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sclafani, F., Peckitt, C., Cunningham, D., Tait, D., Giralt, J., Glimelius, B., . . . Chau, I. (2015). Short-and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(2), 303-312. doi:10.1016/j.ijrobp.2015.03.038

Chand, M., Palmer, T., Blomqvist, L., Nagtegaal, I., West, N., & Brown, G. (2015). Evidence for radiological and histopathological prognostic importance of detecting extramural venous invasion in rectal cancer: recommendations for radiology and histopathology reporting. COLORECTAL DISEASE, 17(6), 468-473. doi:10.1111/codi.12920

Machado, I., Brown, G., Estevan, R., Salud, A., Gil, M., Montagut, C., . . . Fernandez-Martos, C. (2015). Radiologic and pathologic prognostic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-year update GEMCAD 0801-trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2015.33.3_suppl.643

Sclafani, F., Chau, I., Cunningham, D., Lampis, A., Hahne, J., Braconi, C., . . . Valeri, N. (2015). Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2015.33.3_suppl.581

2014

Slesser, A. A. P., Khan, F., Chau, I., Khan, A. Z., Mudan, S., Tekkis, P. P., . . . Rao, S. (2015). The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: An exploratory study. EJSO, 41(4), 484-492. doi:10.1016/j.ejso.2014.12.009

Chand, M., Balyasnikova, S., & Brown, G. (2015). The role of imaging in the diagnosis and staging of primary and recurrent rectal cancer. In Modern Management of Cancer of the Rectum (pp. 81-96). doi:10.1007/978-1-4471-6609-2_6

Rymer, B., Chand, M., Bhangu, A., Swift, I., & Brown, G. (2015). FDG-PET-CT can be used to Assess the Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy: Evidence from Meta-Analysis. In BRITISH JOURNAL OF SURGERY Vol. 102 (pp. 184-185). Harrogate, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346489701210&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Siddiqui, M., Bhoday, J., Abulafi, M. A., Tekkis, P., & Brown, G. (2015). Defining Poor Response after Neoadjuvant Therapy in Patients with Rectal Cancer. In BRITISH JOURNAL OF SURGERY Vol. 102 (pp. 28). Harrogate, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346489700075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Messager, M., Brown, G., & Allum, W. H. (2014). MDCT for Staging of Oesophageal and Junctional Cancer: Do we need a Dedicated Reporting Template?. In BRITISH JOURNAL OF SURGERY Vol. 101 (pp. 38). Brighton, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345329400126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., & Evans, J. (2014). Timing of surgery following chemoradiotherapy in rectal Cancer.. Indian J Med Paediatr Oncol, 35(4), 235-236. doi:10.4103/0971-5851.144959

Kontovounisios, C., Kinross, J., Tan, E., Brown, G., Rasheed, S., & Tekkis, P. (2015). Complete mesocolic excision in colorectal cancer: a systematic review. COLORECTAL DISEASE, 17(1), 7-16. doi:10.1111/codi.12793

Frentzas, S., Thompson, V. L., Vermeulen, P. B., Foo, S., Brown, G., Cunningham, D., & Reynolds, A. R. (2014). Vessel co-option in colorectal cancer liver metastases mediates resistance to VEGF-targeted therapy. In CANCER RESEARCH Vol. 74 (pp. 1 page). San Diego, CA: AMER ASSOC CANCER RESEARCH. doi:10.1158/1538-7445.AM2014-2997

2014

Khan, K., Wale, A., Brown, G., & Chau, I. (2014). Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?. WORLD JOURNAL OF GASTROENTEROLOGY, 20(35), 12391-12406. doi:10.3748/wjg.v20.i35.12391

Chand, M., Evans, J., Swift, R. I., Tekkis, P. P., West, N. P., Stamp, G., . . . Brown, G. (2015). The Prognostic Significance of Postchemoradiotherapy High-resolution MRI and Histopathology Detected Extramural Venous Invasion in Rectal Cancer. ANNALS OF SURGERY, 261(3), 473-479. doi:10.1097/SLA.0000000000000848

Chand, M., Brown, G., Tekkis, P., & Heald, R. J. (2014). Total mesorectal excision optimized by pelvic MRI. COLORECTAL DISEASE, 16(11), 847-853. doi:10.1111/codi.12773

Fernandez-Martos, C., Brown, G., Estevan, R., Salud, A., Montagut, C., Maurel, J., . . . Pericay, C. (2014). Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial. ONCOLOGIST, 19(10), 1042-1043. doi:10.1634/theoncologist.2014-0233

Georgiou, P. A., Bhangu, A., Brown, G., Rasheed, S., Nicholls, R. J., & Tekkis, P. P. (2015). Learning curve for the management of recurrent and locally advanced primary rectal cancer: a single team’s experience. COLORECTAL DISEASE, 17(1), 57-65. doi:10.1111/codi.12772

Battersby, N. J., Balyasnikova, S., & Brown, G. (2014). Guiding Post-Treatment Decisions in Rectal Cancer: mrTRG Is a Practical Place to Start. ONCOLOGY-NEW YORK, 28(8), 677-680. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000340866000003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Wale, A., & Brown, G. (2014). A practical review of the performance and interpretation of staging magnetic resonance imaging for rectal cancer.. Top Magn Reson Imaging, 23(4), 213-223. doi:10.1097/RMR.0000000000000028

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., . . . Chau, I. (2014). TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(7), 4 pages. doi:10.1093/jnci/dju121

Thompson, V., Frentzas, S., Vermeulen, P., Foo, S., Eltahir, Z., Brown, G., . . . Reynolds, A. R. (2014). Proffered Paper: Vessel co-option in colorectal cancer liver metastases mediates resistance to conventional anti-angiogenic therapy. EUROPEAN JOURNAL OF CANCER, 50, S9. doi:10.1016/S0959-8049(14)50032-9

Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Capdevila, J., . . . Chau, I. (2014). Fc gamma RIIa and Fc gamma RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease. CLINICAL CANCER RESEARCH, 20(17), 4511-4519. doi:10.1158/1078-0432.CCR-14-0674

Bhangu, A., Rasheed, S., Brown, G., Tait, D., Cunningham, D., & Tekkis, P. (2014). Does rectal cancer height influence the oncological outcome?. COLORECTAL DISEASE, 16(10), 801-808. doi:10.1111/codi.12703

Chand, M., Siddiqui, M. R. S., Rasheed, S., Brown, G., Tekkis, P., Parvaiz, A., & Qureshi, T. (2014). A systematic review and meta-analysis evaluating the role of laparoscopic surgical resection of transverse colon tumours. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 28(12), 3263-3272. doi:10.1007/s00464-014-3634-3

Battersby, N. J., Moran, B., Yu, S., Tekkis, P., & Brown, G. (2014). MR imaging for rectal cancer: the role in staging the primary and response to neoadjuvant therapy. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 8(6), 703-719. doi:10.1586/17474124.2014.906898

Kennedy, E. D., Milot, L., Fruitman, M., Al-Sukhni, E., Heine, G., Schmocker, S., . . . McLeod, R. S. (2014). Development and Implementation of a Synoptic MRI Report for Preoperative Staging of Rectal Cancer on a Population-Based Level. DISEASES OF THE COLON & RECTUM, 57(6), 700-708. doi:10.1097/DCR.0000000000000123

Sclafani, F., Peckitt, C., Cunningham, D., Evans, J., Brown, G., Tabernero, J., . . . Chau, I. (2014). Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.15_suppl.3575

Watkins, D. J., Starling, N., Cunningham, D., Thomas, J., Webb, J., Brown, G., . . . Chau, I. (2014). The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. EUROPEAN JOURNAL OF CANCER, 50(8), 1422-1429. doi:10.1016/j.ejca.2014.02.003

Chand, M., Bhangu, A., Wotherspoon, A., Stamp, G. W. H., Swift, R. I., Chau, I., . . . Brown, G. (2014). EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. ANNALS OF ONCOLOGY, 25(4), 858-863. doi:10.1093/annonc/mdu029

Chand, M., & Brown, G. (2014). Important imaging considerations in the pre-operative assessment of rectal cancer. Seminars in Colon and Rectal Surgery, 25(1), 6-12. doi:10.1053/j.scrs.2013.11.001

Bhangu, A., Kiran, R. P., Brown, G., Goldin, R., & Tekkis, P. (2014). Establishing the optimum lymph node yield for diagnosis of stage III rectal cancer. TECHNIQUES IN COLOPROCTOLOGY, 18(8), 709-717. doi:10.1007/s10151-013-1114-8

Bhangu, A., Ali, S. M., Brown, G., Nicholls, R. J., & Tekkis, P. (2014). Indications and Outcome of Pelvic Exenteration for Locally Advanced Primary and Recurrent Rectal Cancer. ANNALS OF SURGERY, 259(2), 315-322. doi:10.1097/SLA.0b013e31828a0d22

Khan, K. H., Wale, A., McCall, J., Wijesekera, N., Khan, N., Chau, I., & Brown, G. (2014). The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.3_suppl.622

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., . . . Chau, I. (2014). RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.3_suppl.489

Hill, E. J., Enescu, M., West, N., Franklin, J. M., Chu, K. -Y., Li, J., . . . Sharma, R. A. (2014). Oral nelfinavir before and during radiation therapy for rectal cancer: Changes in tumor perfusion and correlation between tissue and radiological markers of response.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.3_suppl.491

Astin, R., Jack, S., Loughney, L., Barben, C., Grocott, M., Brown, G., & West, M. A. (2014). Training Response To A Structured Exercise Program Is Associated With Greater Tumour Regression In Rectal Cancer Following Neoadjuvant Chemoradiotherapy. In AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Vol. 189 (pp. 2 pages). AMER THORACIC SOC. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209838206461&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sondenaa, K., Quirke, P., Hohenberger, W., Sugihara, K., Kobayashi, H., Kessler, H., . . . Moran, B. (2014). The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 29(4), 419-428. doi:10.1007/s00384-013-1818-2

Watkins, D. J., Starling, N., Chau, I., Thomas, J., Webb, J., Oates, J. R., . . . Cunningham, D. (2010). The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma : The TARGET study.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. doi:10.1200/jco.2010.28.15_suppl.4036

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Giralt, J., . . . Chau, I. (2014). RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. EUROPEAN JOURNAL OF CANCER, 50(8), 1430-1436. doi:10.1016/j.ejca.2014.02.002

Yu, S. K. T., Chand, M., Tait, D. M., & Brown, G. (2014). Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. EUROPEAN JOURNAL OF CANCER, 50(5), 920-927. doi:10.1016/j.ejca.2013.12.007

Chand, M., Moran, B. J., Jones, R. G., Heald, R. J., & Brown, G. (2014). Lymph Node Status Does Not Predict Local Recurrence in the Total Mesorectal Excision Era. DISEASES OF THE COLON & RECTUM, 57(1), 127-129. doi:10.1097/DCR.0000000000000001

Waage, J., Taylor, F., Read, J., & Brown, G. (2014). Imaging assessment of early rectal cancer.. Recent Results Cancer Res, 203, 3-14. doi:10.1007/978-3-319-08060-4_1

Battersby, N. J., Balyasnikova, S., & Brown, G. (2014). Guiding post-treatment decisions in rectal cancer: mrTRG is a practical place to start.. Oncology (Williston Park, N.Y.), 28(8), 677-680.

Tudyka, V., Blomqvist, L., Beets-Tan, R. G. H., Boelens, P. G., Valentini, V., van de Velde, C. J., . . . Brown, G. (2014). EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: The radiology experts review. EJSO, 40(4), 469-475. doi:10.1016/j.ejso.2013.10.029

Chand, M., Swift, R. I., Chau, I., Heald, R. J., Tekkis, P. P., & Brown, G. (2014). Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 96(7), 543-546. doi:10.1308/003588414X13814021678835

Yu, S. K. T., Bhangu, A., Tait, D. M., Tekkis, P., Wotherspoon, A., & Brown, G. (2014). Chemoradiotherapy response in recurrent rectal cancer. CANCER MEDICINE, 3(1), 111-117. doi:10.1002/cam4.169

Chand, M., Yu, S., Swift, R. I., & Brown, G. (2014). Mucinous carcinoma of the rectum: a distinct clinicopathological entity. TECHNIQUES IN COLOPROCTOLOGY, 18(4), 335-344. doi:10.1007/s10151-013-1099-3

Chand, M., Swift, R. I., Tekkis, P. P., Chau, I., & Brown, G. (2014). Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. BRITISH JOURNAL OF CANCER, 110(1), 19-25. doi:10.1038/bjc.2013.603

Bhangu, A., Kiran, R. P., Slesser, A., Fitzgerald, J. E., Brown, G., & Tekkis, P. (2013). Survival After Resection of Colorectal Cancer Based on Anatomical Segment of Involvement. ANNALS OF SURGICAL ONCOLOGY, 20(13), 4161-4168. doi:10.1245/s10434-013-3104-5

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B. J., Blomqvist, L., Swift, I. R., . . . Brown, G. (2014). Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. JOURNAL OF CLINICAL ONCOLOGY, 32(1), 34-U114. doi:10.1200/JCO.2012.45.3258

How, P., West, N. P., & Brown, G. (2014). An MRI-based Assessment of Standard and Extralevator Abdominoperineal Excision Specimens: Time for a Patient Tailored Approach?. ANNALS OF SURGICAL ONCOLOGY, 21(3), 822-828. doi:10.1245/s10434-013-3378-7

Moran, B. J., Holm, T., Brannagan, G., Chave, H., Quirke, P., West, N., . . . McMeeking, A. (2014). The English National Low Rectal Cancer Development Programme: key messages and future perspectives. COLORECTAL DISEASE, 16(3), 173-178. doi:10.1111/codi.12501

Chand, M., Rasheed, S., Bhangu, A., Stamp, G. W. H., Swift, R. I., Tekkis, P. P., & Brown, G. (2014). Adjuvant chemotherapy improves overall survival after TME surgery in mucinous carcinoma of the rectum. EJSO, 40(2), 240-245. doi:10.1016/j.ejso.2013.11.005

Bhangu, A., Wood, G., Brown, G., Darzi, A., Tekkis, P., & Goldin, R. (2014). The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. COLORECTAL DISEASE, 16(4), O133-O143. doi:10.1111/codi.12482

2013

Yu, S. K. T., Tait, D., Chau, I., & Brown, G. (2013). MRI Predictive Factors for Tumor Response in Rectal Cancer Following Neoadjuvant Chemoradiation Therapy – Implications for Induction Chemotherapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(3), 505-511. doi:10.1016/j.ijrobp.2013.06.2052

van de Velde, C. J. H., Boelens, P. G., Borras, J. M., Coebergh, J. -W., Cervantes, A., Blomqvist, L., . . . Valentini, V. (2014). EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. EUROPEAN JOURNAL OF CANCER, 50(1), 34 pages. doi:10.1016/j.ejca.2013.06.048

Tam, H. H., Collins, D. J., Brown, G., Chau, I., Cunningham, D., Leach, M. O., & Koh, D. -M. (2013). The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. BRITISH JOURNAL OF RADIOLOGY, 86(1030), 8 pages. doi:10.1259/bjr.20130281

Chand, M., Heald, R. J., & Brown, G. (2013). The importance of not overstaging mesorectal lymph nodes seen on MRI. COLORECTAL DISEASE, 15(10), 1201-1204. doi:10.1111/codi.12435

Bhangu, A., Kiran, R., Patel, P., Brown, G., & Tekkis, P. (2013). Survival after resection of colorectal cancer based on anatomical segment of involvement. BRITISH JOURNAL OF SURGERY, 100, 62. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326083400186&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Slesser, A. A. P., Chand, M., Goldin, R., Brown, G., Tekkis, P. P., & Mudan, S. (2013). Outcomes of simultaneous resections for patients with synchronous colorectal liver metastases. EJSO, 39(12), 1384-1393. doi:10.1016/j.ejso.2013.09.012

Sclafani, F., Cunningham, D., Tabernero, J., Glimelius, B., Cervantes, A., Peckitt, C., . . . Chau, I. (2013). Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S487). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843603224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., . . . Chau, I. (2013). TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial. EUROPEAN JOURNAL OF CANCER, 49, S4. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209470600012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Chand, M., & Brown, G. (2013). Pre-operative staging of rectal cancer: MRI or ultrasound?. Seminars in Colon and Rectal Surgery, 24(3), 114-118. doi:10.1053/j.scrs.2013.03.002

van de Velde, C. J. H., Aristei, C., Boelens, P. G., Beets-Tan, R. G. H., Blomqvist, L., Borras, J. M., . . . Valentini, V. (2013). EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. EUROPEAN JOURNAL OF CANCER, 49(13), 2784-2790. doi:10.1016/j.ejca.2013.04.032

Bhangu, A., Brown, G., Nicholls, R. J., Wong, J., Darzi, A., & Tekkis, P. (2013). Survival Outcome of Local Excision versus Radical Resection of Colon or Rectal Carcinoma A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study. ANNALS OF SURGERY, 258(4), 563-571. doi:10.1097/SLA.0b013e3182a4e85a

Nougaret, S., Reinhold, C., Mikhael, H. W., Rouanet, P., Bibeau, F., & Brown, G. (2013). The Use of MR Imaging in Treatment Planning for Patients with Rectal Carcinoma: Have You Checked the “DISTANCE”?. RADIOLOGY, 268(2), 329-343. doi:10.1148/radiol.13121361

Dighe, S., Blake, H., Jeyadevan, N., Castellano, I., Koh, D. -M., Orton, M., . . . Brown, G. (2013). Perfusion CT Vascular Parameters Do Not Correlate with Immunohistochemically Derived Microvessel Density Count in Colorectal Tumors. RADIOLOGY, 268(2), 400-410. doi:10.1148/radiol.13112460

Bott, R., Chand, M., Bhoday, J., Swift, R. I., & Brown, G. (2013). MRI-detected EMVI (Mremvi) should be considered in addition to histopathological EMVI status with regards to treatment decisions in rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 100 (pp. 130-131). Glasgow, SCOTLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326083400392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Beynon, J., Brown, G., Chang, G., Das, P., Desai, A., . . . Woodhouse, C. (2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. BRITISH JOURNAL OF SURGERY, 100(8), E1-E33. doi:10.1002/bjs.9192

Patel, U. B., & Brown, G. (2013). MRI-based assessment of tumor regression in rectal cancer. Current Colorectal Cancer Reports, 9(2), 136-145. doi:10.1007/s11888-013-0169-2

Bott, R. K., Chand, M., Nash, G. F., Swift, R. I., & Brown, G. (2013). The role of MRI in treatment planning for rectal cancer – a review. Current Cancer Therapy Reviews, 9(2), 111-116. doi:10.2174/1573394711309020003

Costa-Silva, L., & Brown, G. (2013). Magnetic Resonance Imaging of Rectal Cancer. MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 21(2), 385-+. doi:10.1016/j.mric.2013.01.006

Bhangu, A., Fitzgerald, E., Brown, G., & Tekkis, P. (2012). Indications and outcomes of abdominosacral resection for locally advanced primary and recurrent rectal cancer. BRITISH JOURNAL OF SURGERY, 99, 106-107. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306123100325&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Slesser, A. A. P., Simillis, C., Goldin, R., Brown, G., Mudan, S., & Tekkis, P. P. (2013). A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. SURGICAL ONCOLOGY-OXFORD, 22(1), 36-47. doi:10.1016/j.suronc.2012.11.002

Bhangu, A., Ali, S. M., Cunningham, D., Brown, G., & Tekkis, P. (2013). Comparison of long-term survival outcome of operative vs nonoperative management of recurrent rectal cancer. COLORECTAL DISEASE, 15(2), 156-163. doi:10.1111/j.1463-1318.2012.03123.x

Slesser, A. A. P., Georgiou, P., Brown, G., Mudan, S., Goldin, R., & Tekkis, P. (2013). The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. CLINICAL & EXPERIMENTAL METASTASIS, 30(4), 457-470. doi:10.1007/s10585-012-9551-8

Morton, U. K. D., Seymour, M., Magill, L., Handley, K., Brown, G., Ferry, D., . . . Gray, R. (2012). Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. LANCET ONCOLOGY, 13(11), 1152-1160. doi:10.1016/S1470-2045(12)70348-0

Dighe, S., Castellano, E., Blake, H., Jeyadevan, N., Koh, M. U., Orten, M., . . . Brown, G. (2012). Perfusion CT to assess angiogenesis in colon cancer: technical limitations and practical challenges. BRITISH JOURNAL OF RADIOLOGY, 85(1018), E814-E825. doi:10.1259/bjr/19855447

Bhangu, A., Brown, G., Akmal, M., & Tekkis, P. (2012). Outcome of abdominosacral resection for locally advanced primary and recurrent rectal cancer. BRITISH JOURNAL OF SURGERY, 99(10), 1453-1461. doi:10.1002/bjs.8881

Patel, U. B., Blomqvist, L. K., Taylor, F., George, C., Guthrie, A., Bees, N., & Brown, G. (2012). MRI After Treatment of Locally Advanced Rectal Cancer: How to Report Tumor Response-The MERCURY Experience. AMERICAN JOURNAL OF ROENTGENOLOGY, 199(4), W486-W495. doi:10.2214/AJR.11.8210

Chand, M., Bhoday, J., Brown, G., Moran, B., & Parvaiz, A. (2012). Laparoscopic surgery for rectal cancer. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 105(10), 429-435. doi:10.1258/jrsm.2012.120070

Georgiou, P. A., Tekkis, P. P., Constantinides, V. A., Patel, U., Goldin, R. D., Darzi, A. W., . . . Brown, G. (2013). Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 49(1), 72-81. doi:10.1016/j.ejca.2012.06.025

Slesser, A. A. P., Bhangu, A., Brown, G., Mudan, S., & Tekkis, P. P. (2013). The management of rectal cancer with synchronous liver metastases: a modern surgical dilemma. TECHNIQUES IN COLOPROCTOLOGY, 17(1), 1-12. doi:10.1007/s10151-012-0888-4

2012

Hunter, C., Brown, G., Temple, L., Abulafi, M., & Arnaout, A. (2012). Magnetic resonance imaging assisted tumour block selection in colorectal cancer. VIRCHOWS ARCHIV, 461, S179. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310364801512&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Patel, U. B., Brown, G., Rutten, H., West, N., Sebag-Montefiore, D., Glynne-Jones, R., . . . Quirke, P. (2012). Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. ANNALS OF SURGICAL ONCOLOGY, 19(9), 2842-2852. doi:10.1245/s10434-012-2309-3

Shihab, O. C., Heald, R. J., Holm, T., How, P. D., Brown, G., Quirke, P., & Moran, B. J. (2012). A pictorial description of extralevator abdominoperineal excision for low rectal cancer. COLORECTAL DISEASE, 14(10), E655-E660. doi:10.1111/j.1463-1318.2012.03181.x

Al-Sukhni, E., Milot, L., Fruitman, M., Beyene, J., Victor, J. C., Schmocker, S., . . . Kennedy, E. (2012). Diagnostic Accuracy of MRI for Assessment of T Category, Lymph Node Metastases, and Circumferential Resection Margin Involvement in Patients with Rectal Cancer: A Systematic Review and Meta-analysis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2212-2223. doi:10.1245/s10434-011-2210-5

How, P., Evans, J., Moran, B., Swift, I., & Brown, G. (2012). Preoperative MRI sphincter morphology and anal manometry: can they be markers of functional outcome following anterior resection for rectal cancer?. COLORECTAL DISEASE, 14(6), E339-E345. doi:10.1111/j.1463-1318.2012.02942.x

Dewdney, A., Chau, I., Capdevila, J., Glimelius, B., Cervantes-Ruiperez, A., Tait, D. M., . . . Cunningham, D. (2012). The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009804716&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Fernandez-Martos, C., Estevan, R., Salud, A., Pericay, C., Gallen, M., Sierra, E., . . . Brown, G. (2012). Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803825&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Bharat Patel, U., Santos Cores, J., Gil Garcia, M. I., Ramon Ayuso, J., Puchades Roman, I., . . . Fernandez-Martos, C. (2012). Comparison of magnetic resonance imaging and histopathological response to neoadjuvant chemotherapy in locally advanced rectal cancer: The GEMCAD 0801 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802738&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Ali, M., Cunningham, D., Brown, G., & Tekkis, P. P. (2012). Comparison of long-term survival outcomes of operative versus nonoperative management of recurrent rectal cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009800867&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Dewdney, A., Cunningham, D., Tabernero, J., Capdevila, J., Glimelius, B., Cervantes, A., . . . Chau, I. (2012). Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1620-1627. doi:10.1200/JCO.2011.39.6036

Dighe, S., Swift, I., Magill, L., Handley, K., Gray, R., Quirke, P., . . . Brown, G. (2012). Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. COLORECTAL DISEASE, 14(4), 438-444. doi:10.1111/j.1463-1318.2011.02638.x

Starling, N., Hawkes, E. A., Chau, I., Watkins, D., Thomas, J., Webb, J., . . . Cunningham, D. (2012). A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. ANNALS OF ONCOLOGY, 23(4), 942-947. doi:10.1093/annonc/mdr317

Brown, G., Evans, J., Tait, D., Swift, I., Tekkis, P., Wotherspoon, A., & Chau, I. (2012). Timing of Surgery Following Preoperative Therapy in Rectal Cancer: There Is No Need for a Prospective Randomized Trial Reply. DISEASES OF THE COLON & RECTUM, 55(3), E31-E32. doi:10.1097/DCR.0b013e31823f86dd

West, N., Hemmings, G. J., Richman, S. D., Taylor, M., Chambers, P., Magill, L., . . . Quirke, P. (2012). KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial. In JOURNAL OF PATHOLOGY Vol. 226 (pp. S4). Dept Cellular Pathol, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000300669800010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

West, N., Tinkler-Hundal, E., Handley, K., Magill, L., Lancaster, D., Seymour, M., . . . Quirke, P. (2012). Histopathological Downstaging of Colon Cancer Following Six Weeks of Pre-operative Chemotherapy: Early Results of the NCRI FOxTROT Trial. In JOURNAL OF PATHOLOGY Vol. 226 (pp. S23). Dept Cellular Pathol, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000300669800083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Ali, S. M., Darzi, A., Brown, G., & Tekkis, P. (2012). Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. COLORECTAL DISEASE, 14(12), 1457-1466. doi:10.1111/j.1463-1318.2012.03005.x

Yu, S. K., Brown, G., & Tait, D. M. (2012). Use of MRI-defined tumor distance from the anal verge to predict tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.. J Clin Oncol, 30(4_suppl), 573. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27983202

Currie, A. C., Evans, J., Smith, N. J., Brown, G., Abulafi, A. M., & Swift, R. I. (2012). The impact of the two-week wait referral pathway on rectal cancer survival. COLORECTAL DISEASE, 14(7), 848-853. doi:10.1111/j.1463-1318.2011.02829.x

Brown, G. (2012). Specialist multidisciplinary team working in the treatment of cancer Improves survival, possibly through enabling bolder treatment. BMJ-BRITISH MEDICAL JOURNAL, 344, 2 pages. doi:10.1136/bmj.e2780

Tam, H. H., Collins, D. J., Wallace, T., Brown, G., Riddell, A., & Koh, D. -M. (2012). Segmental liver hyperintensity in malignant biliary obstruction on diffusion weighted MRI: associated MRI findings and relationship with serum alanine aminotransferase levels. BRITISH JOURNAL OF RADIOLOGY, 85(1009), 22-28. doi:10.1259/bjr/24852804

Bhangu, A., Slesser, A., Brown, G., & Tekkis, P. (2012). Indications and outcomes of pelvic exenteration for locally advanced primary and recurrent rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 99 (pp. 70-71). Liverpool, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306123100208&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Ali, M., Cunningham, D., Brown, G., & Tekkis, P. (2012). Comparison of long-term survival outcomes of operative versus non-operative management of recurrent rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 99 (pp. 95). Liverpool, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306123100284&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

2011

Hunter, C. J., Garant, A., Vuong, T., Artho, G., Lisbona, R., Tekkis, P., . . . Brown, G. (2012). Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment. ANNALS OF SURGICAL ONCOLOGY, 19(4), 1199-1205. doi:10.1245/s10434-011-2036-1

Pedersen, B. G., Moran, B., Brown, G., Blomqvist, L., Fenger-Gron, M., & Laurberg, S. (2011). Reproducibility of Depth of Extramural Tumor Spread and Distance to Circumferential Resection Margin at Rectal MRI: Enhancement of Clinical Guidelines for Neoadjuvant Therapy. AMERICAN JOURNAL OF ROENTGENOLOGY, 197(6), 1360-1366. doi:10.2214/AJR.11.6508

Shihab, O. C., Taylor, F., Bees, N., Blake, H., Jeyadevan, N., Bleehen, R., . . . Brown, G. (2011). Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. BRITISH JOURNAL OF SURGERY, 98(12), 1798-1804. doi:10.1002/bjs.7662

Shihab, O. C., Taylor, F., Salerno, G., Heald, R. J., Quirke, P., Moran, B. J., & Brown, G. (2011). MRI Predictive Factors for Long-Term Outcomes of Low Rectal Tumours. ANNALS OF SURGICAL ONCOLOGY, 18(12), 3278-3284. doi:10.1245/s10434-011-1776-2

Chand, M., & Brown, G. (2012). What are the relevant imaging factors to optimize treatment decisions?. In Multidisciplinary Management of Rectal Cancer: Questions and Answers (Vol. 9783642250057, pp. 27-39). doi:10.1007/978-3-642-25005-7_4

Evans, J., Tait, D., Swift, I., Pennert, K., Tekkis, P., Wotherspoon, A., . . . Brown, G. (2011). Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial?. DISEASES OF THE COLON & RECTUM, 54(10), 1251-1259. doi:10.1097/DCR.0b013e3182281f4b

Chua, S., Georgiou, P., Brown, G., Cook, G., Drake, B., Antoniou, A., & Tekkis, P. (2011). The added value of combined 18F-FDG PET-MRI in the preoperative assessment of local tumour invasion in recurrent and locally advanced primary rectal cancer using pelvic compartmental analysis. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S194. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619400368&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Chand, M., & Brown, G. (2012). How can we identify tumour penetration?. In Multidisciplinary Management of Rectal Cancer: Questions and Answers (Vol. 9783642250057, pp. 59-65). doi:10.1007/978-3-642-25005-7_7

Shihab, O. C., How, P., West, N., George, C., Patel, U., Quirke, P., . . . Brown, G. (2011). Can a Novel MRI Staging System for Low Rectal Cancer Aid Surgical Planning?. DISEASES OF THE COLON & RECTUM, 54(10), 1260-1264. doi:10.1097/DCR.0b013e31822abd78

Chua, S., Yu, S., Drake, B., Patel, U., Tait, D., Cook, G., . . . Brown, G. (2011). A prospective multicentre study to evaluate the diagnostic ability of multimodality imaging (FDG PET/CT, MRI and DW-MRI) in detecting early rectal tumour regrowth in cases of deferral of rectal surgery following continued response to preoperative chemoradiotherapy(CRT). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S157. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619400236&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G. (2011). Commentary: MRI should not predict histopathological involved margins. COLORECTAL DISEASE, 13(9), 982-983. doi:10.1111/j.1463-1318.2011.02717.x

Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., . . . Chau, I. (2011). A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. ANNALS OF ONCOLOGY, 22(9), 2042-2048. doi:10.1093/annonc/mdq714

Patel, U. B., Taylor, F., Blomqvist, L., George, C., Evans, H., Tekkis, P., . . . Brown, G. (2011). Magnetic Resonance Imaging-Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience. JOURNAL OF CLINICAL ONCOLOGY, 29(28), 3753-3760. doi:10.1200/JCO.2011.34.9068

Evans, J., Patel, U., & Brown, G. (2011). Rectal Cancer: Primary Staging and Assessment After Chemoradiotherapy. SEMINARS IN RADIATION ONCOLOGY, 21(3), 169-177. doi:10.1016/j.semradonc.2011.02.002

Hawkes, E. A., Cunningham, D., Tait, D., Brown, G., & Chau, I. (2011). Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. SEMINARS IN RADIATION ONCOLOGY, 21(3), 196-202. doi:10.1016/j.semradonc.2011.02.005

Glimelius, B., Beets-Tan, R., Blomqvist, L., Brown, G., Nagtegaal, I., Pahlman, L., . . . van de Velde, C. (2011). Mesorectal Fascia Instead of Circumferential Resection Margin in Preoperative Staging of Rectal Cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(16), 2142-2143. doi:10.1200/JCO.2010.34.4473

How, P., Shihab, O., Tekkis, P., Brown, G., Quirke, P., Heald, R., & Moran, B. (2011). A systematic review of cancer related patient outcomes after anterior resection and abdominoperineal excision for rectal cancer in the total mesorectal excision era. SURGICAL ONCOLOGY-OXFORD, 20(4), E149-E155. doi:10.1016/j.suronc.2011.05.001

Morton, D., Magill, L., Handley, K., Brown, G., Ferry, D. R., Gray, Z. B., . . . FOxTROT Collaborative Group. (2011). FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report.. J Clin Oncol, 29(15_suppl), 3568. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28020286

Morton, D., Magill, L., Handley, K., Brown, G., Ferry, D. R., Gray, Z. B., . . . Gray, R. G. (2011). FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. doi:10.1200/jco.2011.29.15_suppl.3568

Dewdney, A., Capdevila, J., Glimelius, B., Cervantes, A., Tait, D. M., Brown, G., . . . Cunningham, D. (2011). EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.. J Clin Oncol, 29(15_suppl), 3513. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28020332

Dewdney, A., Capdevila, J., Glimelius, B., Cervantes, A., Tait, D. M., Brown, G., . . . Cunningham, D. (2011). EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. doi:10.1200/jco.2011.29.15_suppl.3513

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., . . . Brown, G. (2011). One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. BRITISH JOURNAL OF SURGERY, 98(6), 872-879. doi:10.1002/bjs.7458

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., . . . MERCURY study group. (2011). Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.. Ann Surg, 253(4), 711-719. doi:10.1097/SLA.0b013e31820b8d52

Hunter, C., Garant, A., Vuong, T., Artho, G., Lisbona, R., Abulafi, M., & Brown, G. (2011). Potential therapeutic impact of routine pre-operative staging with FDG-PET/CT in high and low risk rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 98 (pp. 36). Royal Coll Surgery, Dublin, IRELAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290664500120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Pedersen, B. G., Blomqvist, L., Brown, G., Fenger-Gron, M., Moran, B., & Laurberg, S. (2011). Postgraduate Multidisciplinary Development Program: Impact on the Interpretation of Pelvic MRI in Patients With Rectal Cancer: A Clinical Audit in West Denmark. DISEASES OF THE COLON & RECTUM, 54(3), 328-334. doi:10.1007/DCR.0b013e3182031e83

Georgiou, P. A., Tekkis, P. P., Patel, U., Antoniou, A., Darzi, A. W., Cunningham, D., . . . Brown, G. (2011). The added value of diffusion-weighted magnetic resonance imaging (DW-MRI) in the local staging of advanced colorectal pelvic cancer.. J Clin Oncol, 29(4_suppl), 378. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985528

Georgiou, P. A., Tekkis, P. P., Patel, U., Antoniou, A., Darzi, A. W., Cunningham, D., . . . Brown, G. (2011). The added value of diffusion-weighted magnetic resonance imaging (DW-MRI) in the local staging of advanced colorectal pelvic cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. doi:10.1200/jco.2011.29.4_suppl.378

Hunter, C. J., Scurr, E., Jeyadevan, N., Collins, D. J., Abulafi, M., Tekkis, P. P., . . . Brown, G. (2011). Optimising magnetic resonance imaging for preoperative staging and surgical planning in colon cancer at 1.5 tesla and 3.0 tesla.. J Clin Oncol, 29(4_suppl), 395. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985624

Hunter, C. J., Scurr, E., Jeyadevan, N., Collins, D. J., Abulafi, M., Tekkis, P. P., . . . Brown, G. (2011). Optimising magnetic resonance imaging for preoperative staging and surgical planning in colon cancer at 1.5 tesla and 3.0 tesla. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. doi:10.1200/jco.2011.29.4_suppl.395

Dewdney, A., Cunningham, D., Tabernero, J., Glimelius, B., Cervantes, A., Tait, D. M., . . . Chau, I. (2011). EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer.. J Clin Oncol, 29(4_suppl), 360. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985488

Dewdney, A., Cunningham, D., Tabernero, J., Glimelius, B., Cervantes, A., Tait, D. M., . . . Chau, I. (2011). EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208847100358&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Tekkis, P. P., Georgiou, P. A., Constantinides, V. A., Patel, U., Antoniou, A., Goldin, R. D., . . . Brown, G. (2011). Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal pelvic cancer.. J Clin Oncol, 29(4_suppl), 370. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985511

Tekkis, P. P., Georgiou, P. A., Constantinides, V. A., Patel, U., Antoniou, A., Goldin, R. D., . . . Brown, G. (2011). Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal pelvic cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. doi:10.1200/jco.2011.29.4_suppl.370

Yu, S. K., Brown, G., Heald, R. J., Chua, S., Cook, G., Barbachano, Y., . . . Tait, D. M. (2011). Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom.. J Clin Oncol, 29(4_suppl), 489. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985501

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., . . . Brown, G. (2011). Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone A Prospective, Multicenter, European Study. ANNALS OF SURGERY, 253(4), 711-719. doi:10.1097/SLA.0b013e31820b8d52

Georgiou, P. A., Tekkis, P. P., & Brown, G. (2011). Pelvic colorectal recurrence: crucial role of radiologists in oncologic and surgical treatment options.. Cancer Imaging, 11 Spec No A, S103-S111. doi:10.1102/1470-7330.2011.9025

2010

Shihab, O. C., Quirke, P., Heald, R. J., Moran, B. J., & Brown, G. (2010). Magnetic resonance imaging-detected lymph nodes close to the mesorectal fascia are rarely a cause of margin involvement after total mesorectal excision. BRITISH JOURNAL OF SURGERY, 97(9), 1431-1436. doi:10.1002/bjs.7116

Dighe, S., Purkayastha, S., Swift, I., Tekkis, P. P., Darzi, A., A’Hern, R., & Brown, G. (2010). Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. CLINICAL RADIOLOGY, 65(9), 708-719. doi:10.1016/j.crad.2010.01.024

Dighe, S., Blake, H., Koh, M. -D., Swift, I., Arnaout, A., Temple, L., . . . Brown, G. (2010). Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. BRITISH JOURNAL OF SURGERY, 97(9), 1407-1415. doi:10.1002/bjs.7096

Koh, D. -M., George, C., Temple, L., Collins, D. J., Toomey, P., Raja, A., . . . Brown, G. (2010). Diagnostic Accuracy of Nodal Enhancement Pattern of Rectal Cancer at MRI Enhanced With Ultrasmall Superparamagnetic Iron Oxide: Findings in Pathologically Matched Mesorectal Lymph Nodes. AMERICAN JOURNAL OF ROENTGENOLOGY, 194(6), W505-W513. doi:10.2214/AJR.08.1819

Fernandez-Martos, C., Safont, M., Feliu, J., Pericay, C., Gallen, M., Vera, R., . . . Brown, G. (2010). Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. doi:10.1200/jco.2010.28.15_suppl.tps196

Gray, R. G., Morton, D., Brown, G., Ferry, D. R., Magill, L., Quirke, P., . . . Warren, B. (2010). FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. doi:10.1200/jco.2010.28.15_suppl.tps192

Chua, Y. J., Barbachano, Y., Cunningham, D., Oates, J. R., Brown, G., Wotherspoon, A., . . . Chau, I. (2010). Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. LANCET ONCOLOGY, 11(3), 241-248. doi:10.1016/S1470-2045(09)70381-X

Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., nicholls, R. J., & Tekkis, P. (2010). Lateral pelvic lymph-node dissection: still an option for cure Reply. LANCET ONCOLOGY, 11(2), 114-115. doi:10.1016/S1470-2045(10)70015-2

Watkins, D. J., Chau, I., Cunningham, D., Mudan, S. S., Karanjia, N., Brown, G., . . . Gillbanks, A. (2010). Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. BRITISH JOURNAL OF CANCER, 102(2), 255-261. doi:10.1038/sj.bjc.6605508

Taylor, F., Mangat, N., Swift, I. R., & Brown, G. (2010). Proforma-based reporting in rectal cancer.. Cancer Imaging, 10 Spec no A, S142-S150. doi:10.1102/1470-7330.2010.9092

Shihab, O. C., Brown, G., Daniels, I. R., Heald, R. J., Quirke, P., & Moran, B. J. (2010). Patients With Low Rectal Cancer Treated by Abdominoperineal Excision Have Worse Tumors and Higher Involved Margin Rates Compared With Patients Treated by Anterior Resection. DISEASES OF THE COLON & RECTUM, 53(1), 53-56. doi:10.1007/DCR.0b013e3181c70465

2009

Shihab, O. C., Heald, R. J., Rullier, E., Brown, G., Holm, T., Quirke, P., & Moran, B. J. (2009). Defining the surgical planes on MRI improves surgery for cancer of the low rectum. LANCET ONCOLOGY, 10(12), 1207-1211. doi:10.1016/S1470-2045(09)70084-1

Starling, N., Watkins, D., Cunningham, D., Thomas, J., Webb, J., Brown, G., . . . Chau, I. (2009). Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(33), 5499-5505. doi:10.1200/JCO.2008.21.5384

Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., Nicholls, R. J., & Tekkis, P. (2009). Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. LANCET ONCOLOGY, 10(11), 1053-1062. doi:10.1016/S1470-2045(09)70224-4

Leary, A., Assersohn, L., Cunningham, D., Norman, A. R., Chong, G., Brown, G., . . . Oates, J. (2009). A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 64(3), 455-462. doi:10.1007/s00280-008-0893-5

O’Neill, B. D. P., Salerno, G., Thomas, K., Tait, D. M., & Brown, G. (2009). MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. BRITISH JOURNAL OF RADIOLOGY, 82(978), 509-513. doi:10.1259/bjr/60198873

Starling, N., Okines, A., Cunningham, D., Allum, W., Wotherspoon, A., Benson, M., . . . Chau, I. (2009). A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. BRITISH JOURNAL OF CANCER, 100(11), 1725-1730. doi:10.1038/sj.bjc.6605070

Salerno, G. V., Daniels, I. R., Moran, B. J., Heald, R. J., Thomas, K., & Brown, G. (2009). Magnetic Resonance Imaging Prediction of an Involved Surgical Resection Margin in Low Rectal Cancer. DISEASES OF THE COLON & RECTUM, 52(4), 632-639. doi:10.1007/DCR.0b013e3181a0a37e

Shihab, O. C., Moran, B. J., Heald, R. J., Quirke, P., & Brown, G. (2009). MRI staging of low rectal cancer. EUROPEAN RADIOLOGY, 19(3), 643-650. doi:10.1007/s00330-008-1184-6

Potter, K. C., Husband, J. E., Houghton, S. L., Thomas, K., & Brown, G. (2009). Diagnostic Accuracy of Serial CT/Magnetic Resonance Imaging Review vs. Positron Emission Tomography/CT in Colorectal Cancer Patients with Suspected and Known Recurrence. DISEASES OF THE COLON & RECTUM, 52(2), 253-259. doi:10.1007/DCR.0b013e31819d11e6

Koh, D. -M., Brown, G., & Collins, D. J. (2009). Nanoparticles in rectal cancer imaging. CANCER BIOMARKERS, 5(2), 89-98. doi:10.3233/CBM-2009-0544

2008

Dighe, S., Swift, I., & Brown, G. (2008). CT staging of colon cancer. CLINICAL RADIOLOGY, 63(12), 1372-1379. doi:10.1016/j.crad.2008.04.021

Taylor, F. G. M., Swift, R. I., Blomqvist, L., & Brown, G. (2008). A Systematic Approach to the Interpretation of Preoperative Staging MRI for Rectal Cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 191(6), 1827-1835. doi:10.2214/AJR.08.1004

Smith, N. J., Shihab, O., Arnaout, A., Swift, R. I., & Brown, G. (2008). MRI for Detection of Extramural Vascular Invasion in Rectal Cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 191(5), 1517-1522. doi:10.2214/AJR.08.1298

Salerno, G., Chandler, I., Wotherspoon, A., Thomas, K., Moran, B., & Brown, G. (2008). Sites of surgical waisting in the abdominoperineal specimen. BRITISH JOURNAL OF SURGERY, 95(9), 1147-1154. doi:10.1002/bjs.6231

Brown, G. (2008). MRI: STAGING AND RE-STAGING AFTER PREOPERATIVE TREATMENT, NEW CONTRAST AGENTS. In RADIOTHERAPY AND ONCOLOGY Vol. 88 (pp. S128). ELSEVIER IRELAND LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433281200354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

ONeill, B., Tait, D., & Brown, G. (2008). ANASTOMOTIC LOCAL RECURRENCE OF RECTAL CANCER REMAINS AN IMPORTANT AND PREVENTABLE PATTERN OF FAILURE FOLLOWING TOTAL MESORECTAL EXCISION: LESSONS FOR RADIOTHERAPISTS. In RADIOTHERAPY AND ONCOLOGY Vol. 88 (pp. S87). ELSEVIER IRELAND LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433281200248&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Kong, G., Jackson, C., Koh, D. M., Lewington, V., Sharma, B., Brown, G., . . . Cook, G. J. R. (2008). The use of F-18-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 35(7), 1323-1329. doi:10.1007/s00259-008-0743-z

Koh, D. -M., Chau, I., Tait, D., Wotherspoon, A., Cunningham, D., & Brown, G. (2008). Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(2), 456-461. doi:10.1016/j.ijrobp.2007.10.016

Koh, D. M., Brown, G., Riddell, A. M., Scurr, E., Collins, D. J., Allen, S. D., . . . Husband, J. E. (2008). Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. EUROPEAN RADIOLOGY, 18(5), 903-910. doi:10.1007/s00330-007-0847-z

Moran, B., Brown, G., Cunningham, D., Daniels, I., Heald, R., Quirke, P., & Sebag-Montefiore, D. (2008). Clarifying the TNM staging of rectal cancer in the context of modern imaging and neo-adjuvant treatment: ‘y”u’ and ‘p’ need ‘mr’ and ‘ct’. COLORECTAL DISEASE, 10(3), 242-243. doi:10.1111/j.1463-1318.2007.01260.x

Smith, N. J., Barbachano, Y., Norman, A. R., Swift, R. I., Abulafi, A. M., & Brown, G. (2008). Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. BRITISH JOURNAL OF SURGERY, 95(2), 229-236. doi:10.1002/bjs.5917

Koh, D. M., Dzik-Jurasz, A., O’Neill, B., Tait, D., Husband, J. E., & Brown, G. (2008). Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. BRITISH JOURNAL OF RADIOLOGY, 81(962), 91-98. doi:10.1259/bjr/96187638

Park, S. H. (2008). Degree of error of thin-section MR in measuring extramural depth of tumor invasion in patients with rectal cancer.. Radiology, 246(2), 647. doi:10.1148/radiol.2462070843

Brown, G., & Norman, A. R. (2008). Degree of error of thin-section MR in measuring extramural depth of tumor invasion in patients with rectal cancer – Response. RADIOLOGY, 246(2), 648. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000252796300049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Koh, D. -M., Smith, N. J., Swift, R. I., & Brown, G. (2008). The Relationship Between MR Demonstration of Extramural Venous Invasion and Nodal Disease in Rectal Cancer.. Clin Med Oncol, 2, 267-273. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21892288

O’Neill, B., Brown, G., Wotherspoon, A., Burton, S., Norman, A., & Tait, D. (2008). Successful downstaging of high rectal and recto-sigmoid cancer by neo-adjuvant chemo-radiotherapy.. Clin Med Oncol, 2, 135-144. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21892276

Brown, G. (2008). Staging rectal cancer: endoscopic ultrasound and pelvic MRI.. Cancer Imaging, 8 Spec No A, S43-S45. doi:10.1102/1470-7330.2008.9008

Smith, N., & Brown, G. (2008). Preoperative staging of rectal cancer. ACTA ONCOLOGICA, 47(1), 20-31. doi:10.1080/02841860701697720

O’Neill, B. D. P., Tait, D. M., & Brown, G. (2008). Anastomotic local recurrence of rectal cancer remains an important and preventable pattern of failure following total mesorectal excision: Lessons for radiotherapists. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 72 (pp. S246). Boston, MA: ELSEVIER SCIENCE INC. doi:10.1016/j.ijrobp.2008.06.635

Burton, S., Brown, G., Bees, N., Norman, A., Biedrzycki, O., Arnaout, A., . . . Swift, R. I. (2008). Accuracy of CT prediction of poor prognostic features in colonic cancer. BRITISH JOURNAL OF RADIOLOGY, 81(961), 10-19. doi:10.1259/bjr/19492531

2007

O’Neill, B. D. P., Brown, G., Cunningham, D., Heald, R. J., & Tait, D. M. (2007). Chemoradiotherapy alone for rectal cancer: A word of caution – Reply. LANCET ONCOLOGY, 8(10), 862-863. doi:10.1016/S1470-2045(07)70293-0

O’Neill, B., Chaldecott, R., Brown, G., Sharma, R. A., Norman, A., Scurr, E., . . . Tait, D. M. (2007). Optimisation of radiotherapy planning for rectal cancer: a comparison of supine CT and MRI defined target and normal tissue dose volume data. In EJC SUPPLEMENTS Vol. 5 (pp. 258). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD. doi:10.1016/S1359-6349(07)71001-7

Brown, G. (2007). Imaging of liver metastases (CT scan, MRI, PET scan). EJC SUPPLEMENTS, 5(5), 297-300. doi:10.1016/S1359-6349(07)70056-3

O’Neill, B. D. P., Brown, G., Heald, R. J., Cunningham, D., & Tait, D. M. (2007). Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. LANCET ONCOLOGY, 8(7), 625-633. doi:10.1016/S1470-2045(07)70202-4

Watkins, D. J., Jackson, C., Chua, Y., Chong, G., Norman, A. R., Brown, G., . . . Cunningham, D. (2007). A prospective study of oxaliplatin and capecitabine (CapOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043700678&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Salerno, G., Daniels, I. R., Brown, G., Norman, A. R., Moran, B. J., & Heald, R. J. (2007). Variations in pelvic dimensions do not predict the risk of circumferential resection margin (CRM) involvement in rectal cancer. WORLD JOURNAL OF SURGERY, 31(6), 1313-1320. doi:10.1007/s00268-007-9007-5

Smith, N. J., Bees, N., Barbachano, Y., Norman, A. R., Swift, R. I., & Brown, G. (2007). Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. BRITISH JOURNAL OF CANCER, 96(7), 1030-1036. doi:10.1038/sj.bjc.6603646

Fowler, J. M., Beagley, C. E., Blomqvist, L., Brown, G., Daniels, I. R., Heald, R. J., . . . Sebag-Montefiore, D. (2007). Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: Results of the MERCURY Study. RADIOLOGY, 243(1), 132-139. doi:10.1148/radiol.2431051825

Riddell, A. M., Allum, W. H., Thompson, J. N., Wotherspoon, A. C., Richardson, C., & Brown, G. (2007). The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. EUROPEAN RADIOLOGY, 17(2), 391-399. doi:10.1007/s00330-006-0363-6

Koh, D. -M., Brown, G., Meer, Z., Norman, A. R., & Husband, J. E. (2007). Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. AMERICAN JOURNAL OF ROENTGENOLOGY, 188(2), W154-W161. doi:10.2214/AJR.05.1421

Starling, N., & Brown, G. (2007). Patterns of recurrence following therapy for rectal cancer. In Colorectal Cancer (pp. 233-247). doi:10.1017/CBO9780511902468.013

Burton, S., & Brown, G. (2007). MRI staging. In Colorectal Cancer (pp. 174-211). doi:10.1017/CBO9780511902468.011

Brown, G. (2007). Imaging of metastatic disease. In Colorectal Cancer (pp. 212-232). doi:10.1017/CBO9780511902468.012

Riddell, A. M., Davies, D. C., Allum, W. H., Wotherspoon, A. C., Richardson, C., & Brown, G. (2007). High-resolution MRI in evaluation of the surgical anatomy of the esophagus and posterior mediastinum. AMERICAN JOURNAL OF ROENTGENOLOGY, 188(1), W37-W43. doi:10.2214/AJR.05.1795

Burton, S., & Brown, G. (2007). CT staging. In Colorectal Cancer (pp. 157-173). doi:10.1017/CBO9780511902468.010

Brown, G., Reznek, R. H., & Husband, J. E. (2007). Colorectal cancer. doi:10.1017/CBO9780511902468

2006

Petroudi, S., Brown, G., Bond, S., & Brady, M. (2006). Circumferential resection margin assessment on MRI of rectal cancer.. Conference proceedings : … Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference, 4881-4884.

Riddell, A. M., Richardson, C., Scurr, E., & Brown, G. (2006). The development and optimization of high spatial resolution Mill for imaging the oesophagus using an external surface coil. BRITISH JOURNAL OF RADIOLOGY, 79(947), 873-879. doi:10.1259/bjr/36989440

Riddell, A. M., Hillier, J., Brown, G., King, D. M., Wotherspoon, A. C., Thompson, J. N., . . . Allum, W. H. (2006). Potential of surface-coil MRI for staging of esophageal cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 187(5), 1280-1287. doi:10.2214/AJR.05.0559

Koh, D. M., Brown, G., & Husband, J. E. (2006). Nodal staging in rectal cancer. ABDOMINAL IMAGING, 31(6), 652-659. doi:10.1007/s00261-006-9021-3

Salerno, G., Daniels, I. R., Brown, G., Heald, R. J., & Moran, B. J. (2006). Magnetic resonance imaging pelvimetry in 186 patients with rectal cancer confirms an overlap in pelvic size between males and females. COLORECTAL DISEASE, 8(9), 772-776. doi:10.1111/j.1463-1318.2006.01090.x

Salerno, G., Daniels, I. R., Moran, B. J., Wotherspoon, A., & Brown, G. (2006). Clarifying margins in the multidisciplinary management of rectal cancer: the MERCURY experience. CLINICAL RADIOLOGY, 61(11), 916-923. doi:10.1016/j.crad.2006.06.005

Heald, R. J., O’Neill, B. D. P., Moran, B., Brown, G., Darzi, A. W., Wotherspoon, A. C., . . . Tait, D. M. (2006). MRI in predicting curative resection of rectal cancer – New dilemma in multidisciplinary team management. BMJ-BRITISH MEDICAL JOURNAL, 333(7572), 808. doi:10.1136/bmj.333.7572.808

Brown, G., Daniels, I. R., Heald, R. J., Quirke, P., Blomqvist, L., Sebag-Montefiore, D., . . . Mason, B. (2006). Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BRITISH MEDICAL JOURNAL, 333(7572), 779-782. doi:10.1136/bmj.38937.646400.55

Chau, I., Cunningham, D., Tait, D., & Brown, G. (2006). Role of neoadjuvant chemotherapy in rectal cancer: Interpretation of the EXPERT study – Reply. JOURNAL OF CLINICAL ONCOLOGY, 24(28), 4665-4666. doi:10.1200/JCO.2006.08.2206

Salerno, G., Daniels, I. R., & Brown, G. (2006). Magnetic resonance imaging of the low rectum: defining the radiological anatomy. COLORECTAL DISEASE, 8, 10-13. doi:10.1111/j.1463-1318.2006.01063.x

Daniels, I. R., Fisher, S. E., Brown, G., Heald, R. J., & Moran, B. J. (2006). Complexities and controversies in the management of low rectal cancer: Proceedings of the 3rd Pelican Surgical Symposium 2005. COLORECTAL DISEASE, 8, 3-4. doi:10.1111/j.1463-1318.2006.01061.x

Koh, D. M., Scurr, E., Collins, D. J., Pirgon, A., Kanber, B., Karanjia, N., . . . Husband, J. E. (2006). Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. EUROPEAN RADIOLOGY, 16(9), 1898-1905. doi:10.1007/s00330-006-0201-x

Burton, S., Norman, A. R., Brown, G., Abulafi, A. M., & Swift, R. I. (2006). Predictive poor prognostic factors in colonic carcinoma. SURGICAL ONCOLOGY-OXFORD, 15(2), 71-78. doi:10.1016/j.suronc.2006.08.003

Chong, G., Starling, N., Norman, A. R., Brown, G., Thomas, J., Ross, P. J., & Cunningham, D. C. (2006). Phase II study of fixed dose rate gemcitabine in patients with pretreated advanced colorectal cancer.. J Clin Oncol, 24(18_suppl), 13558. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27952203

Rutten, H., Sebag-Montefiore, D., Glynne-Jones, R., Rullier, E., Peeters, M., Brown, G., . . . Quirke, P. (2006). Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 153S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009401046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Rutten, H., Sebag-Montefiore, D., Glynne-Jones, R., Rullier, E., Peeters, M., Brown, G., . . . Quirke, P. (2006). Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study.. J Clin Oncol, 24(18_suppl), 3528. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27953296

Pitt-Francis, J., Chen, D., Slaymaker, M., Simpson, A., Brady, M., van Leeuwen, I., . . . Gavaghan, D. (2006). Multimodal imaging techniques for the extraction of detailed geometrical and physiological information for use in multi-scale models of colorectal cancer and treatment of individual patients. Computational and Mathematical Methods in Medicine, 7(2-3), 177-188. doi:10.1080/10273660600969083

Burton, S., Brown, G., Daniels, I., Norman, A., Swift, I., Abulafi, M., . . . Tait, D. (2006). MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: Treatment with radiotherapy and chemotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 65(2), 445-451. doi:10.1016/j.ijrobp.2005.12.027

Burton, S., Brown, G., Daniels, I. R., Norman, A. R., Mason, B., & Cunningham, D. (2006). MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. BRITISH JOURNAL OF CANCER, 94(3), 351-357. doi:10.1038/sj.bjc.6602947

Chan, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., . . . Oates, J. (2006). Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(4), 668-674. doi:10.1200/JCO.2005.04.4875

Riddell, A., Allum, W., Thompson, J., Wotherspoon, A., Cunningham, D., & Brown, G. (2006). The impact of high resolution MRI for determining operability of esophageal cancer. In ANNALS OF ONCOLOGY Vol. 17 (pp. 90). Barcelona, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239782000282&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

O’Neill, B. D. P., Brown, G., & Tait, D. M. (2006). Successful downstaging of upper rectal and distal sigmoid tumours by preoperative chemo-radiotherapy. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 66 (pp. S302). Philadelphia, PA: ELSEVIER SCIENCE INC. doi:10.1016/j.ijrobp.2006.07.570

Smith, N., Norman, A., Swift, I., & Brown, G. (2006). MRI detects extra-mural vascular invasion and predicts outcome in colorectal cancer. In ANNALS OF ONCOLOGY Vol. 17 (pp. 24-25). Barcelona, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239782000022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Salerno, G., Daniels, I., & Brown, G. (2006). Low rectal cancers at the intersphincteric plane are at high risk of close resection margins: An analysis of the mercury study MRI scans. In ANNALS OF ONCOLOGY Vol. 17 (pp. 45-46). Barcelona, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239782000102&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Petroudi, S., Brown, G., Bond, S., & Brady, M. (2006). Circumferential resection margin assessment on MRI of rectal cancer.. Conf Proc IEEE Eng Med Biol Soc, 1, 4881-4884. doi:10.1109/IEMBS.2006.259277

Petroudi, S., Brown, G., Bond, S., & Brady, M. (2006). Circumferential resection margin assessment on MRI of rectal cancer. In 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-15 (pp. 3851-+). New York, NY: IEEE. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247284704116&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

2005

Brown, G., & Zbar, A. P. (2005). MRI in colorectal surgery: Surface magnetic resonance imaging in anorectal practice. In Complex Anorectal Disorders: Investigation and Management (pp. 275-297). doi:10.1007/1-84628-057-5_17

Sebag-Montefiore, D., Brown, G., Rutten, H., Rullier, E., Peeters, M., Glynne-Jones, R., . . . Van de Velde, C. (2005). An international phase II study of Capecitabine, Oxaliplatin, Radiotherapy and Excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results. EJC SUPPLEMENTS, 3(2), 170. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247564800586&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Koh, D. M., Brown, G., Temple, L., Blake, H., Raja, A., Toomey, P., . . . Husband, J. E. (2005). Distribution of mesorectal lymph nodes in rectal cancer: in vivo MR imaging compared with histopathological examination. Initial observations. EUROPEAN RADIOLOGY, 15(8), 1650-1657. doi:10.1007/s00330-005-2751-8

Assersohn, L., Norman, A. R., Chong, G., Brown, G., Ross, P. J., Costello, C., . . . Cunningham, D. (2005). Phase II trial evaluating capecitabine and irinotecan in patients (pts) with esophago-gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 350S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326602221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Starling, N., Brown, G., Tait, D., Norman, A., & Cunningham, D. (2005). Patterns of pelvic recurrence in patients with rectal cancers treated with adjuvant chemotherapy in a multicentre randomised study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 271S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326601496&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Daniels, I. R., Richardson, C., Revell, P., Peppercorn, D., & Bourne, M. (2005). Techniques and trouble-shooting in high spatial resolution thin slice MRI for rectal cancer. BRITISH JOURNAL OF RADIOLOGY, 78(927), 245-251. doi:10.1259/bjr/33540239

Brown, G., Daniels, I. R., & Quirke, P. (2005). MRI predicts surgical resection margin status in patients with rectal cancer. – Results from the MERCURY study group. In JOURNAL OF PATHOLOGY Vol. 205 (pp. 13). London, ENGLAND: JOHN WILEY & SONS LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000227614000051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Daniels, I. R., Brown, G., & Quirke, P. (2005). High spatial resolution MRI predicts tumour spread in patients with rectal cancer – Results from the MERCURY study group. In JOURNAL OF PATHOLOGY Vol. 205 (pp. 13). London, ENGLAND: JOHN WILEY & SONS LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000227614000053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G. (2005). Thin section MRI in multidisciplinary pre-operative decision making for patients with rectal cancer. BRITISH JOURNAL OF RADIOLOGY, 78, S117-S127. doi:10.1259/bjr/15128198

Brown, G., & Daniels, I. R. (2005). Preoperative staging of rectal cancer: the MERCURY research project.. Recent Results Cancer Res, 165, 58-74. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15865021

2004

Salerno, G., Daniels, I., Heald, R. J., Brown, G., & Moran, B. J. (2004). Management and imaging of low rectal carcinoma. SURGICAL ONCOLOGY-OXFORD, 13(2-3), 55-61. doi:10.1016/j.suronc.2004.09.013

Burton, S., Daniels, I., Brown, G., Stellakis, M., Chau, I., Swift, I. R., . . . Cunningham, D. (2004). Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. 272S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512401079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Burton, S., Daniels, I., Brown, G., Stellakis, M., Chau, I., Swift, I. R., . . . Cunningham, D. (2004). Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting.. J Clin Oncol, 22(14_suppl), 3611. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28014328

Brown, G., Davies, S., Williams, G. T., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., . . . Maughan, T. S. (2004). Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?. BRITISH JOURNAL OF CANCER, 91(1), 23-29. doi:10.1038/sj.bjc.6601871

Salerno, G., Daniels, I., Croxford, M., Brown, G., & Heald, R. J. (2004). Preoperative radiotherapy for rectal cancer. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 97(7), 361-362. doi:10.1258/jrsm.97.7.361-b

Blomqvist, L. (2004). Colorectal cancer imaging. AMERICAN JOURNAL OF ROENTGENOLOGY, 182(6), 1600-1601. doi:10.2214/ajr.182.6.1821600a

Chau, I., Allen, M. J., Cunningham, D., Norman, A. R., Brown, G., Ford, H. E. R., . . . Oates, J. (2004). The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1420-1429. doi:10.1200/JCO.2004.05.041

Koh, D. M., Brown, G., Temple, L., Raja, A., Toomey, P., Bett, N., . . . Husband, J. E. (2004). Rectal cancer: Mesorectal lymph nodes at MR Imaging with USPIO versus histopathologic findings – Initial observations. RADIOLOGY, 231(1), 91-99. doi:10.1148/radiol.2311030142

Brown, G. (2004). Local radiological staging of rectal cancer. CLINICAL RADIOLOGY, 59(3), 213-214. doi:10.1016/j.crad.2003.10.001

Snelling, J. D., Abdullah, N., Brown, G., King, D. M., Moskovic, E., & Gui, G. P. H. (2004). Measurement of tumour size in case selection for breast cancer therapy by clinical assessment and ultrasound. EJSO, 30(1), 5-9. doi:10.1016/j.ejso.2003.10.003

Snelling, J. D., Abdullah, N., Brown, G., King, D. M., Moskovic, E., & Gui, G. P. H. (2004). Measurement of tumour size in case selection for breast cancer therapy by clinical assessment and ultrasound. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 30(1), 5-9. doi:10.1016/j.ejso.2003.10.003

Brown, G., Kirkham, A., Williams, G. T., Bourne, M., Radcliffe, A. G., Sayman, J., . . . Heald, R. J. (2004). High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. AMERICAN JOURNAL OF ROENTGENOLOGY, 182(2), 431-439. doi:10.2214/ajr.182.2.1820431

Assersohn, L., Brown, G., Cunningham, D., Ward, C., Oates, J., Waters, J. S., . . . Norman, A. R. (2004). Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ANNALS OF ONCOLOGY, 15(1), 64-69. doi:10.1093/annonc/mdh007

Heald, R. J., Moran, B. J., Brown, G., & Daniels, I. R. (2004). Optimal total mesorectal excision for rectal cancer is by dissection in front of Denonvilliers’ fascia. BRITISH JOURNAL OF SURGERY, 91(1), 121-123. doi:10.1002/bjs.4386

2003

Brown, G. (2003). Imaging of the liver in metastatic disease. EJC SUPPLEMENTS, 1(6), 159-171. doi:10.1016/S1359-6349(03)90020-6

Chau, I., Cunningham, D., Tait, D., Brown, G., Tebbutt, N., Hill, M., . . . Massey, A. (2003). Twelve weeks of neoadjuvant capecitabine (cap) and oxaliplatin (ox) followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S20). BOURNEMOUTH, ENGLAND: NATURE PUBLISHING GROUP. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000184042200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Richards, C. J., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., Dallimore, N. S., & Williams, G. T. (2003). Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. RADIOLOGY, 227(2), 371-377. doi:10.1148/radiol.2272011747

Chau, I., Allen, M., Cunningham, D., Tait, D., Brown, G., Hill, M., . . . Prior, Y. (2003). Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. BRITISH JOURNAL OF CANCER, 88(7), 1017-1024. doi:10.1038/sj.bjc.6600822

Brown, G., Radcliffe, A. G., Newcombe, R. G., Dallimore, N. S., Bourne, M. W., & Williams, G. T. (2003). Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. BRITISH JOURNAL OF SURGERY, 90(3), 355-364. doi:10.1002/bjs.4034

Chau, I., Kelleher, M. T., Cunningham, D., Norman, A. R., Wotherspoon, A., Trott, P., . . . Bishop, L. (2003). Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients. BRITISH JOURNAL OF CANCER, 88(3), 354-361. doi:10.1038/sj.bjc.6600738

2002

Brown, G., Drury, A. E., Cunningham, D., & Husband, J. E. S. (2003). CT detection of hydronephrosis in resected colorectal cancer: a predictor of recurrent disease. CLINICAL RADIOLOGY, 58(2), 137-142. doi:10.1053/crad.2002.1123

Tan, S. M., Behranwala, K. A., Trott, P. A., Nasim, N. A., Moskovic, E., Brown, G., . . . Gui, G. P. H. (2002). Erratum: A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma (European Journal of Surgical Oncology (2002) vol. 28 (203-8)). European Journal of Surgical Oncology, 28(8), 900. doi:10.1053/ejso.2002.1368

Bartram, C., & Brown, G. (2002). Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 31(3), 827-+. doi:10.1016/S0889-8553(02)00027-4

Dzik-Jurasz, A., Domenig, C., George, M., Wolber, J., Padhani, A., Brown, G., & Doran, S. (2002). Diffusion MRI for prediction of response of rectal cancer to chemoradiation. LANCET, 360(9329), 307-308. doi:10.1016/S0140-6736(02)09520-X

Tan, S. M., Behranwala, K. A., Trott, P. A., Nasim, N. A., Moskovic, E., Brown, G., . . . Gui, G. P. H. (2002). A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 28(3), 203-208. doi:10.1053/ejso.2001.1236

2001

Tan, S. M., Behranwala, K. A., Nasiri, N., Trott, P. A., King, D. M., Moskovic, E., . . . Gui, G. P. H. (2001). Triple assessment in the preoperative diagnosis of invasive tabular breast carcinoma: A comparison of the individual modalities. Breast Cancer Research and Treatment, 69(3), 297.

Whitehouse, P. A., Barber, Y., Brown, G., Moskovic, E., King, D. M., & Gui, G. P. H. (2001). Office ultrasound by breast surgeons: A rapid, accurate adjunct to clinical diagnosis. Breast Cancer Research and Treatment, 69(3), 237.

George, M. L., Dzik-Jurasz, A. S. K., Padhani, A. R., Brown, G., Tait, D. M., Eccles, S. A., & Swift, R. I. (2001). Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. BRITISH JOURNAL OF SURGERY, 88(12), 1628-1636. doi:10.1046/j.0007-1323.2001.01947.x

George, M. L., Dzik-Jurasz, A. S. K., Brown, G., Padhani, A. R., Husband, J., Leach, M. O., . . . Swift, R. I. (2001). Dynamic contrast MRI (DCMRI) assessment of tumour permeability in locally advanced rectal cancer: a prognostic indicator for response to chemoradiotherapy. BRITISH JOURNAL OF SURGERY, 88, 25. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168603000077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Radcliffe, A., & Brown, G. (2001). Will MRI provide maps of lines of excision for rectal cancer?. LANCET, 357(9255), 495-496. doi:10.1016/S0140-6736(00)04038-1

Whitehouse, P. A., Baber, Y., Brown, G., Moskovic, E., King, D. M., & Gui, G. P. H. (2001). The use of ultrasound by breast surgeons in outpatients: an accurate extension of clinical diagnosis. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 27(7), 611-616. doi:10.1053/ejso.2001.1201

2000

Brown, G. (2000). The role of MRI in the local staging of rectal cancer. In Cancer Imaging Vol. 1 (pp. 7-10).

Brown, G. (2000). CT patterns of recurrent disease in colorectal cancer. In Cancer Imaging Vol. 1 (pp. 14-17).

Brown, G. (2000). The role of MRI in the pre-operative staging of rectal cancer. Imaging, 12(2), 141-150. doi:10.1259/img.12.2.120141

1999

Brown, G., Richards, C. J., Newcombe, R. G., Dallimore, N. S., Radcliffe, A. G., Carey, D. P., . . . Williams, G. T. (1999). Rectal carcinoma: Thin-section MR imaging for staging in 28 patients. RADIOLOGY, 211(1), 215-222. doi:10.1148/radiology.211.1.r99ap35215

Brown, G., Phillips, S., Cochlin, D., Bourne, M. W., & Jenkins, B. (1997). Dynamic magnetic resonance imaging of the testis: Preliminary results. British Journal of Urology, 79(SUPPL. 4), 20.

BROWN, G., & SHAW, D. G. (1995). INFLAMMATORY PSEUDOTUMORS IN CHILDREN – CT AND ULTRASOUND APPEARANCES WITH HISTOPATHOLOGICAL CORRELATION. CLINICAL RADIOLOGY, 50(11), 782-786. doi:10.1016/S0009-9260(05)83220-9

BROWN, G., MACVICAR, D. A., AYTON, V., & HUSBAND, J. E. (1995). THE ROLE OF INTRAVENOUS CONTRAST ENHANCEMENT IN MAGNETIC-RESONANCE-IMAGING OF PROSTATIC-CARCINOMA. CLINICAL RADIOLOGY, 50(9), 601-606. doi:10.1016/S0009-9260(05)83288-X

Schon, F., Brown, G., & Britton, J. (1995). Tuberculous myelopathy: a serial MRI study.. J Neurol Neurosurg Psychiatry, 58(2), 259-260. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7876874

BROWN, G., WARREN, M., WILLIAMS, J. E., ADAM, E. J., & COLES, J. A. (1993). CRANIAL COMPUTED-TOMOGRAPHY OF ELDERLY PATIENTS – AN EVALUATION OF ITS USE IN ACUTE NEUROLOGICAL PRESENTATIONS. AGE AND AGEING, 22(4), 240-243. doi:10.1093/ageing/22.4.240

BROWN, G., & HUSBAND, J. E. (1993). MEDIASTINAL WIDENING – A VALUABLE RADIOGRAPHIC SIGN OF SUPERIOR VENA-CAVA THROMBOSIS. CLINICAL RADIOLOGY, 47(6), 415-420. doi:10.1016/S0009-9260(05)81063-3

МРТ рака прямой кишки

5 февраля 2020

Продано!

Адрес: Доброслободская 5, Москва (после регистрации вы получите email с подробной информацией о месте проведения)

sb pic 2 to loadДоктор Светлана Балясникова, старший преподаватель Imperial College London, к.м.н., врач-рентгенолог The Royal Marsden Hospital с 2013 года, работающий под руководством Проф. Джины Браун, на примере клинических случаев проведет детальный разбор современных аспектов и методов МР-диагностики рака прямой кишки. Уникальность Курса заключается в возможности участников самостоятельно разобрать реальные клинические случаи на индивидуальных рабочих станциях под руководством доктора Балясниковой, задать вопросы и получить детальные пояснения. Участников также ждет прямое видео включение из Лондона, во время которого Проф.

Джина Браун расскажет о современных методах стратификации пациентов и подходах в лечении рака прямой кишки в зависимости от стадии заболевания. В течение дня будboth pic 2 to loadут подробно разобраны вопросы диагностики, стадирования и оценки эффективности лечения местно-распространенных форм рака, определения резектабельности и диагностики рецидивов. По окончанию курса слушателей получат электронный буклет со всеми презентациями и наиболее информативными клиническими случаями. Также полезным бонусом для слушателей курса будет получение сертификата Британского Королевского Колледжа Рентгенологов (The Royal College of Radiologists).

при поддержке «Российского общества специалистов по колоректальному раку» и «НМИЦ онкологии им.Н.Н.Блохина»

Due to open

Please click on trial you wish to know more about

PRESERVE

z retired Rectal MRI Two Day Intensive Workshop with Hands On Workstation Practice

2021 courses – booking opening soon

We are running all our courses virtually for the foreseeable future due to the current COVID situation.  

The courses are run in the same way with the same content with a mixture of lectures and hands on virtual workstation practice.

Audience: radiologists, surgeons and oncologists

This course will equip you to ensure high quality MRI in your institution and to be able to evaluate baseline and post treatment MRI assessment of rectal cancer and pelvic anatomy with confidence for your daily practice.

The workshop will provide you with essential knowledge for MDT working and MRI assessment in different clinical scenarios with details revision of anatomy and interpretation criteria with hands on workstation practice for assessing rectal cancer cases and pelvic anatomy and how this is applied to treatment planning.

View Programme

For teams participating in MINSTREL, TRIGGER  trials, you will be certified as having sufficient training to take delegated responsibility for trial participation.

18 CPD points

REGISTRATION:   £635 

2021 dates:

  • 13th 14th January 2021
  • 17th 18th March 2021
  • 2nd 3rd June 2021
  • 15th 16th September 2021
  • 3rd 4th November 2021

Please email me when booking opens for 2021 courses

Achieving Successful Frontline Clinical Research in a DGH

Celebrating 20 Years of Patient Focused Research at Croydon University Hospital

The DGH environment is a perfect space to do excellent clinical research. Please join us and be part of the collaboration to build a future in research together!

Wednesday 10th November 2021

Royal Society of Medicine, 1 Wimpole Street

PROGRAMME

09:00 – 09:30  Registration

09:30 – 09:40  Welcome  Muti Abulafi, Ian Swift, London UK

09:40 – 09:50  Croydon Research and its benefits to the NHS Matthew Kershaw, Chief Executive, Croydon Health Services NHS Trust

09:45 – 10:00 Roll of honour: fellows, funders and supporters  Gina Brown, London UK

10:00 – 11:10 Setting the standards: Croydon leading the way in colon cancer research

Highlighting the work of:  Andrew Beggs;  Shwetal Dighe;  Vera Tudyka;  Sarah Burton;  Chris Hunter; Nigel D’Souza;  Neil Smith;  Nigel Day;  Richard Booth

10:50 Expert Panel commentary with audience discussion and voting

11:10 – 11:35 Morning Coffee

11:35 – 12:45 Saving the rectum: precision imaging directing precision surgery

Highlighting the work of: Matt Tutton;  Annabel Shaw;  James Read;  Rachel Carten

10:50 Expert Panel commentary with audience discussion and voting

12:45 – 13:30  Lunch

13:30 – 14:40  Discovering actual pathways of spread: challenging Dukes’ classification in bowel cancer

Highlighting the work of: Andrew Beggs;  Neil Smith;  Amy Lord;  Fiona Taylor;  Manish Chand;  Nigel D’Souza;  Mohammed Siddiqui

14:20  Expert Panel commentary with audience discussion and voting

14:40 – 15:00  Afternoon tea

15:00 – 15:45  Timing is everything: when and if to operate after radiotherapy

Highlighting the work of:  Mark George;  Jess Evans;  Svetlana Balyasnikova;  Fiona Taylor;  Jemma Bhoday

15:40  Expert Panel commentary with audience discussion and voting

15:45 – 16:45  Is there still a place for frontline research in the DGH setting?  Expert Panel commentary with audience discussion and voting

16:45 – 17:00  Closing Remarks  Neil Mortensen, Oxford UK

Please fill in the form below to register your place

First
Last

Privacy Policy

Who we are

Our website address is: https://profginabrown.com.

What personal data we collect and why we collect it

Contact forms

We only retain collected information for as long as necessary to provide you with your requested service. What data we store, we’ll protect within commercially acceptable means to prevent loss and theft, as well as unauthorised access, disclosure, copying, use or modification.

Cookies

If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.

Embedded content from other websites

Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.

These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Please be aware that we have no control over the content and practices of these sites, and cannot accept responsibility or liability for their respective privacy policies.

Analytics

How long we retain your data

If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.

For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where we send your data

We don’t share any personally identifying information publicly or with third-parties, except when required to by law.

You are free to refuse our request for your personal information, with the understanding that we may be unable to provide you with some of your desired services.

Your continued use of our website will be regarded as acceptance of our practices around privacy and personal information. If you have any questions about how we handle user data and personal information, feel free to contact us.


This policy is effective as of 24 June 2018.

test checkout

Learning Hub

Privacy Policy

Your privacy is important to us. It is our policy to respect your privacy regarding any information we may collect from you across our website, https://profginabrown.com, and other sites we own and operate.

We only ask for personal information when we truly need it to provide a service to you. We collect it by fair and lawful means, with your knowledge and consent. We also let you know why we’re collecting it and how it will be used.

We only retain collected information for as long as necessary to provide you with your requested service. What data we store, we’ll protect within commercially acceptable means to prevent loss and theft, as well as unauthorised access, disclosure, copying, use or modification.

We don’t share any personally identifying information publicly or with third-parties, except when required to by law.

Our website may link to external sites that are not operated by us. Please be aware that we have no control over the content and practices of these sites, and cannot accept responsibility or liability for their respective privacy policies.

You are free to refuse our request for your personal information, with the understanding that we may be unable to provide you with some of your desired services.

Your continued use of our website will be regarded as acceptance of our practices around privacy and personal information. If you have any questions about how we handle user data and personal information, feel free to contact us.


This policy is effective as of 24 June 2018.

Dashboard

Please to view this page

Student Registration


disabled

Oooh! Access Denied

You do not have access to this area of the application. Please refer to your system administrator.

Instructor Registration


disabled

Oooh! Access Denied

You do not have access to this area of the application. Please refer to your system administrator.

REGISTRATION

If you do not receive confirmation of your registration and payment details after 2 working days, please email gina.brown@rmh.nhs.uk

If you wish to enquire about complimentary registration please email caroline.martin@rmh.nhs.uk

PRESERVE Patient Portal

“What is there to lose? As with many things in life, it is a matter of weighing up the risk, and with the type of monitoring regime in place – scans and endoscopy – the risk is low and there is still the fall-back option of having the second procedure.”  R.M.

Many patients with early growths in the rectum (back passage) can have a safe removal of the growth through the back passage, and can avoid major abdominal surgery.  However, the majority of  patients are not offered this type of surgery because there has been difficulty in the past in being able to identify who can safely undergo this type of surgery.

We have found a new way of looking at MRI (magnetic resonance imaging) scans that can help us to improve how we find patients that could avoid major surgery and instead have the growth removed through the back passage.  This procedure is known as “local excision”.

In the PRESERVE Trial we want to increase the number of operations that can be performed using local excision, by using this new MRI scan reporting system.

“It would help talking to other patients also going through this journey.”  K.W.

Below is a link to a list of other websites that may be useful to you at different times during your journey.

Resources

 

PRESERVE trial

“If the tumour regrew and I needed a major operation I would still have been happy with the pathway I have followed.”  K.W.

Almost 1/3 of screen detected rectal cancers are limited to the bowel wall without nodal spread, yet 90% undergo major anterior resection or abdominoperineal surgery with a high associated rate of co-morbidity and economic cost. Precision staging of these cancers could stratify surgical therapy and remove the need for radical surgery and instead offer a local, endoluminal excision thus improving rates of surgical clearance of the polyp and any associated dysplasia or cancer.

The trial aims to change the current standards offered to bowel cancer screening and symptomatic patients diagnosed with a significant polyp or early rectal cancer (ERC) and promote a new pathway for ERC management and enhance current therapeutic pathways with state of art staging technologies and intelligent surgical devices.
Six areas to be investigated are:

  • Identification of patients suitable for pathway through both the Bowel Cancer Screening Pathway (BCSP) and symptomatic patients
  • Detailed staging and surgical roadmap to facilitate local excision
  • Implementation of modern surgical innovations/techniques for real time molecular phenotyping and for precision surgery for ERC
  • Histopathological verification of complete excision and biomarker capture
  • Close monitoring of patients following local excision to ensure successful resection for residual/recurrent disease
  • Impact on quality of life and cost effectiveness of pathway

PRESERVE feasibility checklist

Pan London Early Rectal Cancer Meeting

Ensuring patient choice and access to the PRESERVE Trial

1st November 2018, Royal Society of Medicine,  London

“I made some choices; the outcomes are good.  I remain positive.”  K.W.

Multidisciplinary teams attended a day of lectures, expert panel discussions and break out sessions to establish a consistent pathway for early rectal cancer, increasing identification of patients suitable for local excision, and developing the management pathway for early rectal cancer as outlined in the Colorectal Cancer Guidelines (previously published Cancer Alliances in London) and commissioned NHS England service specification.

 

Mr Ken Webster, our Patient Representative on the PRESERVE trial, agreed to take part in a panel with Dr Diana Tait and Prof Gina Brown to discuss his experiences of being diagnosed with rectal cancer, the choices he was given at his consultation and how his life has changed through the treatment he has received.  We were also able to receive comments from other patient representatives prior to the meeting that we were able to present to the audience.

 

“I am very pleased and relieved that the TEMs procedure was successful, thanks to the skill of the consultant and operating team.  I’m happy that the TEMs procedure could be used rather than the more invasive procedure.”  R.M.

Presentation slides

How to set up and maintain the SPECC early rectal cancer MDT   Mr Francesco Di Fabio

Identification and pathway of lesions for organ-preserving local excision approach    Dr Kevin Monahan

Endoscopic submucosal dissection of rectal lesions   Dr Paul O’Toole

TEM TAMIS patient selection  Mr Chris Cunningham

TEM full-thickness techniques and TAMIS  Mr Tony Miles

Improving precision of staging SPECC and early rectal lesions, and road-mapping for local excision    Prof Gina Brown

PRESERVE Project launch    Miss Annabel Shaw

Adjuvant therapy – selective post-excision therapy in moderate and high risk cancers to enable organ preservation   Dr Diana Tait

Assessment and onward guidance following local excision. Defining high, moderate and low risk cancers   Prof Marco Novelli

Early Rectal Cancer Translational research opportunities    Dr Katharina von Loga

Endoscopic submucosal dissection of rectal lesions    Mr Amyn Haji

How to set up and access support for PRESERVE in your hospital  Mr Graham Branagan

 

Delegates attended from:   Amsterdam UMCBasingstoke North Hampshire HospitalBrighton and Sussex University Hospital NHS TrustChelsea & Westminster NHS Foundation TrustChurchill Hospital, OxfordCroydon University HospitalEast and North Herts NHS TrustEast Suffolk and North Essex Foundation TrustEpsom and St Helier University HospitalsHampshire Hospitals NHS TrustImperial College Healthcare NHS TrustKing’s College Hospital NHS Foundation TrustLondon North West University Healthcare NHS TrustOxford University HospitalsRM Partners (London Cancer Alliance)Royal Liverpool and Broadgreen University HospitalsRoyal Marsden NHS Foundation TrustSalisbury NHS Foundation TrustSt George’s University Hospitals NHS Foundation TrustSt Mark’s Hospital; University College London Hospitals NHS Foundation Trust; University Hospitals of North Midlands

Patient Resources

Pelican Cancer Foundation        www.pelicancancer.org/

Charity which drives innovation and development in bowel (colorectal), bladder, prostate and liver cancer treatment through research and education, and advancing precision surgery and treatment. So – our message is different. Our focus is on surgery, which provides the best outcomes and is often neglected.

Bowel Cancer UK    bowelcanceruk.org.uk

Leading UK charity for bowel cancer patients, working to raise awareness of symptoms, promote early diagnosis and encourage open access to treatment choice for those affected by bowel cancer.

Healthtalk.org    healthtalk.org/peoples-experiences/cancer/colorectal-cancer/topics

Healthtalk.org comes from a unique partnership between a charity called DIPEx  and The Health Experiences Research Group or ‘HERG’ at The University of Oxford’s Nuffield Department of Primary Healthcare Sciences.   It provides free, reliable information about health issues, by sharing people’s real-life experiences.

Macmillan Cancer Support    macmillan.org.uk/information-and-support/bowel-cancer

UK charity providing practical advice and support in all areas of life for people diagnosed with cancer including financial and emotional support.

Cart

Your cart is currently empty!


Checkout

My account

Login

Shop

Beyond TME

Assessing outcomes in primary or recurrent rectal or sigmoid cancer with tumour extending beyond the TME plane

The Beyond TME study is a multicentre prospective trial of patients, who require more ex-tensive surgery, using a novel compartmental imaging classification system. Accurate base-line (ie prior to surgery) staging of patients considered for exenterative surgery will enable a higher likelihood of resection of all potentially affected compartments, which is likely to improve R0 rates and survival. At the same time it will enable better selection of those patients with absolute and relative contraindications to surgery, who would potentially benefit from preoperative treatment and prevent unnecessary resections beyond TME planes, a cause of considerable morbidity. All patients that will potentially undergo surgery beyond the Total Mesorectal excision (TME) in the participating centres are eligible for inclusion. Inoperable patients are also included so that their follow-up and quality of life information can be compared to patients in the same cohort who undergo exenterative surgery.

The Beyond TME trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

TRIGGER

The TRIGGER Feasibility Trial

Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good And Poor Responders to Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial

STUDY RATIONALE

The response to preoperative chemoradiotherapy (CRT) in rectal cancer patients is highly variable; up to 30% of patients will achieve a complete or near complete response, and the remainder do not respond sufficiently to survive the disease to the same extent. Although the need for a validated means of pre-operative assessing response to treatment is widely accepted, there has been no reliable method of assessing this response pre-operatively and therefore the current standard of care advocates using the baseline MRI as the reference for the plane of surgery regardless of any assessment of treatment response. Recently, an MRI based tumour regression grade has been developed (mrTRG). Patients with a poor CRT response (mrTRG4&5) have a 5-year overall survival of 27% versus 72% (p=0.001) for a good CRT response (mrTRG1-3). This novel imaging biomarker has been reliable and reproducible between multiple independent radiologists. These findings are encouraging, as it appears that the subgroup of mrTRG 1-2 have a significant chance of complete long-term tumour regression. Although validation of this as a biomarker has been based on prospective evaluation of MRI scans against both pathology and survival outcomes, there is insufficient evidence that this information can be used to alter current treatment decisions.

TRIAL OBJECTIVES

The main objectives of the feasibility trial are to establish the safety and feasibility of recruitment for a larger phase III study. Should feasibility be confirmed then the primary objective of the Phase III trial is to evaluate disease-free survival at 3 years in patients with locally advanced rectal cancer by using mrTRG directed management to selectively offer surgery and additional pre-operative chemotherapy.

The TRIGGER trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

 

SOPRANO

Study Of PRoliferation and Apoptosis in rectal caNcer as predictive and prognostic biOmarkers: a histopathology and imaging analysis (SOPRANO)

Treatment for rectal cancer involves a course of chemo and radiotherapy (CRT) followed by major abdominal surgery to remove the tumour. After MRI scans performed after CRT have shown that up to 40% of patients will have an extremely good response to treatment with no visible residual tumour. Clinicians question the value of major surgery and its associated complications for a cancer that has effectively ‘disappeared’. However, by not operating on patients, are we leaving viable cancer cells behind and putting patients at risk of recurrence? What is needed is a marker that will predict and measure a patient’s response to CRT at a cellular level, in order to confirm and validate the MRI findings.

The DNA in a cancer cell is damaged. A healthy cell would ‘self-destruct’, a process known as apoptosis. However, cancer cells evade apoptosis and replicate in an uncontrolled manner leading to growth of the tumour. CRT works by causing cancer cells to undergo apoptosis. We believe we can use apoptosis as a marker for the cell ‘death’ seen after CRT. The SOPRANO trial will use a special stain for ‘dead cells’ and count the number of cells with DNA damage. This will give an apoptotic index and should directly equate to a patients response to CRT. This together with the MRI findings would enable us to give patients a more accurate picture of how their tumour is likely to behave in the future and whether or not they would require an operation or further drug treatment. SOPRANO will also measure proliferation, which is a marker of continued cancer growth and will add to the biological basis for our treatment decisions.

The SOPRANO trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

 

 

MINSTREL

Mri IN STaging REctal polyp planes (MINSTREL)

Website: http://minstrelstudy.co.uk/

Patients undergoing TEMS can benefit from reduced mortality, impotence, hospi-tal stay and avoiding a stoma that may be associated with pelvic surgery. Currently few of the patients eligible for TEMS are offered it for a variety of reasons that include uncertainties about the risk of leaving residual tumour and the increased risk of subsequent recurrence of cancer within the pelvis. Currently guidelines state there is no role for imaging in assessing the malignant polyp.

We hope to prospectively test our hypothesis that an MRI scan can accurately gauge depth of tumour spread in an unselected group of benign and malignant tumours measuring be-tween 20mm and 50mm in size. We will identify eligible patients awaiting surgery / poly-pectomy and if they consent to our pilot study they will undergo an MRI to assess their tumour which assesses safety at all levels of the rectal wall. Should MRI prove sensitive and specific then we hope to change national guidelines to mandate MRI to standardise assessment and thereby increase the appropriate use of TEMS in the UK.

The MINSTREL trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

6 vs 12

Optimum timing for surgery after pre-operative radiotherapy

In rectal cancer, radiotherapy is frequently given prior to surgery to enable complete removal and reduce recurrence. Uncertainty remains regarding the timing of surgery and a delay to 12-14 weeks has been hypothesised as advantageous.

The 6vs12 trial is a multicentre randomised clinical trial. Individuals diagnosed with rectal cancer of T3 stage and above will be identified at colorectal MDT and offered randomisation between surgery at 6-8 or 12-14 weeks following completion of radiotherapy. PET/CT, pelvic MRI and final histopathology will be used to determine the response to radiotherapy. The degree of down-staging and tumour regression at 6-8 versus 12-14 weeks will then be compared.

The 6 vs 12 trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

 

 

IMPRESS

Improving radical treatment through MRI evaluation of pelvic sigmoid cancers 

IMPRESS is a two group Phase II randomized interventional clinical trial of the use of high resolution MRI for identifying and treating poor prognosis sigmoid cancers. Patients with pelvic sigmoid cancer in the randomised arm will be randomized to either CT (control arm and standard of care) or investigational MRI (next to standard CT) preoperative staging.

The IMPRESS trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

 

Deferral of Surgery

The Timing and Deferral of Rectal Surgery Following a Continued Complete Response to Pre-operative Chemoradiotherapy

There has been growing interest in selecting, pre-operatively, those rectal cancer patients who are likely to achieve pathological complete response (pCR) following pre-operative chemoradiotherapy. This is of particular importance for patients with low rectal cancers who would otherwise require an Abdomino-perineal resection and a permanent stoma.

In those patients with an optimal response on MRI, a ‘scar’ replaces the site of disease, rep-resented by a focal area of low-signal intensity on T2-weighted MR. The precise cellular composition of such an area of low signal intensity cannot be known, and a single MRI scan cannot diagnose complete response. However, if surgery is deferred, then the ‘scar’ may be monitored with serial imaging, clinical examination and CEA to exclude any change. By adopting this approach, the time interval to maximal tumour debulking can be established and identification of true ‘complete responders’ may be made (sustained radiological and clinical complete response for at least 1 year after CRT).

The Deferral of Surgery Trial is a single-centre interventional study. Patients follow a schedule of imaging, endoscopy and clinic appointments over a 10 year period. If a tumour re-grows, patients are quickly referred for surgery. The aim of the study is to show that the percentage of patients who can successfully avoid surgery is at least 10%.

The Deferral of Surgery trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

SERENADE

Screening for synchronous metastases in colorectal cancer with DW-MRI (SERENADE)

SERENADE is a phase II multicentre, interventional study, which aims to establish whether additional staging with liver diffusion-weighted MRI diagnoses more synchronous metastases than CT alone when colorectal cancer is diagnosed.

The accurate and timely diagnosis of metastatic disease is crucial to enable early surgical referral for metastectomy and neoadjuvant treatment. Contrast enhanced CT is the standard imaging modality for the diagnosis of liver metastases, but MRI with liver specific contrast and diffusion weighted imaging (DW-MRI) is regarded as the gold standard for the di-agnosis of liver metastases DW-MRI is quick and as it does not require contrast agents has no significant additional costs, with the standard sequences taking approximately 10 minutes to compete.

The primary objective of this study is will be to show a >5% increase in the incidence of synchronous liver metastases additionally diagnosed by hepatic diffusion weighted MRI when CT is negative or does not confirm the presence of metastatic disease in patients with high risk colorectal cancer—T3c/d, mrEMVI positive.

The SERENADE trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

Sigmoid WISE

The Sigmoid WISE study

We wish to investigate the ‘waist’ in the distal sigmoid mesentery and define the sigmoid. Identification of the level in the distal sigmoid colon and where ‘waisting’ occurs will enable us to stage tumours at this level as high-risk on pre-operative imaging. Definition of the sigmoid colon by anatomical landmarks using MRI will differentiate upper rectal and sigmoid colon tumours to improve management.

Hypothesis

  • There is a narrowing of the upper rectum and the sigmoid mesentery and that this may increase the risk of an incomplete resection.
  • MRI imaging can be used to define the upper extent of the rectum and the beginning of the sigmoid.

Aims

  • To determine whether there is a level at which the ‘waisting’ occurs in the recto-sigmoid mesentery and the variability present within the population
  • To compare anatomical landmarks of the rectosigmoid junction on MRI and histopathology
  • To determine differences in measurements on MRI with CT and histopathology of:
    • the distance of the rectum from the anal verge
    • the length of the “rectosigmoid junction”
    • the dimensions of the mesorectum and mesocolon.

The WISE trial is open for recruitment

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

ctDNA

Circulating tumour DNA rectal cancer and the relationship to extramural venous invasion

In almost one third of rectal cancer patients, cancer spreads through the bowel wall into nearby veins which can be seen on MRI scans (mrEMVI). It has been observed that this is linked with worse survival due to the spread of cancer to the liver and other organs. We think that this may occur by spread of cancer cells in the blood stream and patients who are at risk of cancer spread to the liver and other organs may have increased levels of cancer cells in the blood (ctDNA). Using improved technology, we would like to find out whether patient with mrEMVI positive rectal tumours also have increased levels of ctDNA. If this is proven correct, this may then explain how cancer spreads to other organs.

The ctDNA study is a prospective multi-centre tissue study. To be eligible, patients must have rectal adenocarcinoma which is mrEMVI positive at baseline. 20 patients who re-main mrEMVI positive at the time of surgery and 20 patients who have become mrEMVI negative following pre-operative therapy, will have a blood sample taken pre-surgery and another taken during surgery following the removal of their tumour.

If difference is measured between the amount of cancer cells in the blood between the two cohorts, we may eventually be able to use this test to help guide treatment in the future. Additionally, if we can find a link between the number of cancer cells seen in blood mrEMVI status, we may be able to offer additional treatment to patients who are at higher risk of recurrence.

The ctDNA trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

Professor Gina Brown MBBS MD MRCP FRCR FASCRS (Hon)

Prof Gina Brown 2014 photo

Professor of Gastrointestinal Cancer Imaging, Imperial College London

email: gina.brown@imperial.ac.uk

http://www.slideshare.net/GinaBrown3/presentations

http://scholar.google.com/citations?user=BwinzQIAAAAJ&hl=en

Professor  Gina Brown graduated from King’s College Hospital School of Medicine, London in 1988 and is Professsor of Gastrointestinal Cancer Imaging and Consultant Radiologist at Imperial College.  She has over 150 peer reviewed  publications, and has been the principal supervisor to  more than 10 successfully  awarded  higher degrees in colon and rectal cancer.  She had the title of Professor of Gastrointestinal Cancer Imaging conferred on her by Imperial College London in August 2014.

As the Radiology Faculty lead for the NHS National TME development programme (2003-2006)  and the National cancer action team Low Rectal Cancer Programme (2011-2013), she has been responsible for the training and roll-out of high quality rectal cancer MRI staging to over 180 multidisciplinary colorectal teams through  specialist workshops which have also been run successfully overseas.

She pioneered the investigation of imaging prognostic factors such as MRI prediction of CRM status, assessing response to treatment, assessment of nodes , extramural vascular invasion in colon and rectal cancer and implications for patient outcomes. This led to identification of key imaging predictors of patients at risk of developing local recurrence and metastatic disease now being targeted for treatment in larger phase II/III trials.  Professor Brown developed staging criteria in colon and rectal cancer and standards for reporting now adopted globally. She initiated and developed the UK  Deferral of Surgery trial protocol for rectal cancer patients in response to patients’ desires to avoid permanent stoma and defined the post radiotherapy MRI criteria to identify complete responders eligible for avoidance of surgery  now being tested in the prospective randomised clinical trial, TRIGGER.

MARVEL

Molecular pAthologic and MRI investigation of the prognostic and predictive importance of extramural VEnous invasion in rectaL Cancer

Very little is known about the long-term outcomes and response to CRT on MRI detected ex-tramural venous invasion (mrEMVI). Although mrEMVI is accepted as a marker of poor prog-nosis, whether it has a predictive value and should be specifically treated is not known.

Molecular and genetic profiling provides us with an opportunity to understand the underlying mechanisms which govern clinical behaviour in rectal cancer. It offers the ability to compare the molecular profiles of different subtypes of rectal cancer such as mrEMVI-positive and – negative tumours and whether any changes are observed following CRT. This can then be cor-related with clinical behaviour over the medium and long-term with regards to local recur-rence, distant metastases and overall survival.

MARVEL is a multicentre, observational study that collects data and tissue from patients with rectal adenocarcinoma who have had pre-operative chemoradiotherapy.

Primary endpoint: Difference in Relapse Free Survival (RFS) between EMVI positive and negative (on pre-treatment MRI) patients, measured from date of surgery.

The MARVEL trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

MERCURY II

Low Rectal Cancer Study

With better staging and documentation of the tumours and radial/ circumferential margins (pathologically) preoperatively, a reduction in margin positivity rates can be achieved.

The Low Rectal Cancer Study (short title MERCURY II) is a multicentre observational study of patients with low rectal adenocarcinoma.

The main hypothesis is that accurate MRI staging pre-operatively will allow the correct patients to receive neo-adjuvant chemoradiotherapy (CRT), and also pre-warn the surgeons if the resection margins appear threatened so that the operation can be modified to take this into account, leading to a reduction in margin (CRM) positivity .

The cohort was divided into two analysis populations, phase I, which includes all patients recruited up to and including December 1st 2011, and phase II, including all patients recruited subsequently to March 3rd 2013. Recruitment is now closed and follow-up is due to continue until March 2018.

The MERCURY II trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

 

COMET

Concordance in MRI and Pathology Diagnosis of Extranodal Tumour Deposits

Aims: To assess the concordance between MRI and pathological diagnosis of extranodal tumour deposits (ENTD) using MRI mapping to guide pathologists. Currently we diagnose ENTD on MRI in our unit but this diagnosis has not been prospectively validated against that of pathology. The fact that pathologists in the UK do not routinely use TNM 7 means ENTD are misclassified as lymph nodes (LN). Even when ENTD are seen, they may not be reported if LN are also involved as LN are seen as being the most important factor. We aim to establish the true frequency of ENTD by prospectively correlating MRI diagnosis of ENTD against pathology. If, as we suspect, the frequency of ENTD is far greater than 10% and approaching 40% this would have significant implications for staging classifications and oncological decision making in the MDT setting.

Methods:  This will be a prospective interventional, multi-centre study. Patients will be identified from multidisciplinary team meetings. All patients presenting with primary adenocarcinoma of the rectum and undergoing resectional surgery (with or without prior neo-adjuvant treatment) will be eligible for inclusion in the study. If ENTD are thought to be present, the final MRI prior to surgery will be used to map the location of deposits both pre-operatively, and in real time while the specimen is being cut up. Baseline characteristics, MRI and pathology results and operative details will be anonymised and recorded in a secure database.

Outcomes: The primary outcome will be concordance of MRI and pathology for the detection of ENTD. Secondary outcomes will be MRI and pathology detection of EMVI, LN status and T stage as well as overall and disease free survival.

The COMET trial is open for recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

PRESERVE

Avoiding major surgery and improving quality of life in patients with early rectal cancer

Click below to find out more information about our ground breaking initiative

“It is important having the choice of avoiding major surgery. I came into this knowing the fall-back position was there, and if I needed major surgery later, then I would have it.”  K.W.

Please fill in the form below if you would like further information or have any questions about any aspect of PRESERVE.

Rectal MRI virtual handson workshops

Research driven evidence based understanding of colorectal cancer for the benefit of patients

Audience: radiologists, surgeons and oncologists

The workshop will provide you with essential knowledge for MDT working and MRI assessment in different clinical scenarios with details revision of anatomy and interpretation criteria with hands on workstation practice for assessing rectal cancer cases and pelvic anatomy and how this is applied to treatment planning to optimise patient care through your MDTs.

Registration fee: £635

18 CPD points

We have been asked to provide workshops at times for clinicians all around the world, and so we have timetabled one of our workshops at times more convenient for the Americas and one for the Asian Pacific region. Of course, anyone is welcome to attend any of the courses – just book on a course whose times best suit you.

Click on the course dates below to see start times for each major time zones for that region. Daylight saving has been taken into account for all courses.

Americas
2 consecutive full days

UK start 13:00

Mon, Oct 3, 2022
Tues, Oct 4, 2022

Asian Pacific
4 x half days over 2 consecutive weeks

UK start 05:30

Mon, Apr 04, 2022
Tues, Apr 05, 2022
Mon Apr 11, 2022
Tues, Apr 12, 2022

How is the course run?

We have replicated the real world handson workshop online so there are the same periods of self study, lectures, worked examples, discussions and self assessments as before. The only difference is that we rely more on you to be fully engaged.

We expect you to complete staging of all cases and assessments that we set throughout the course and to submit your answers via our voting app. By doing this Gina can understand how best to tailor her teaching to you. Although she can’t physically stand behind you, through screen sharing she can answer individual questions but in a way that benefits the group. Everyone will be given the opportunity to present case examples in real time so that Gina can pass on practical tips as to how stage in a methodical way when presenting at an MDT.

We aim for you to leave the course not with a list of correct answers to a specific set of cases, but with a set of practical tools that you can use in your MDTs and rectal cancer reporting.

What do I need to attend?

Hardware

External mouse – All programmes will run on a standard computer but you will need a mouse with a scroll button to use the PACS software successfully. A touchpad will not suffice.

Webcam – we are trying to recreate a ‘real world’ workshop as much as possible and so it is important that during lectures and discussions following self study periods that Gina and your fellow delegates are able see you

Software

You will receive links to all of the software in advance of the course so you can make sure you are able to fully participate.

Zoom – what else?  Please practice saying ‘Can you see my screen? ‘ and ‘You’re on mute’…

Cloudshare – a virtual desktop you will access to use Sectra PACS for course teaching and self study. You will be asked to share your screen so please launch this on the same computer as Zoom.

Slido – online voting app used to record assessment answers – we recommend you use this on your phone or another computer so that you don’t have to keep swapping windows.

Course listing

Second Opinion Referral

We are able to provide a second opinion on colon and rectal cancer.

This includes assessment of the primary tumour and arranging multi-specialty review of your case.

Please fill in the form below with your details.

Our Group

prof-gina-brown-2015-photo-web

Professor Gina Brown MBBS, MD, MRCP, FRCR, FASCRS (Hon)

​Professor of GI Radiology and Consultant Radiologist

Imperial College London

email: gina.brown@imperial.ac.uk

Miss Caroline Martin, Research and Business Manager

email: caroline.martin@rmh.nhs.uk;

Mr Ceri Evans, Senior Research Nurse

Tel: 020 8642 6011 Ext 4208;  Fax: 020 8915 6721;  email: ceri.evans@rmh.nhs.uk

Mrs Syvella Ellis, Trial Manager,

Tel: 020 8915 6067;  Fax: 020 8915 6721;  email: syvella.ellis@rmh.nhs.uk

Ms Ashvina Newoor, Trial Manager

Tel: 020 8915 6495;  Fax 020 8915 6721;  email: ashvina.newoor@rmh.nhs.uk

Mr Mustaphe Muse, Imaging and Specimen Coordinator

Tel: 020 8661 3868;  Fax 020 8915 6721;  email: mustaphe.muse@rmh.nhs.uk

Contact

Please use the form below to contact us.

You are able to register on our courses by going to the ‘Our Courses’ option in the menu, selecting the course you wish to register for and filling in the form on that page.

You are able to ask for information about a specific clinical trial we are running by going to the ‘Clinical Trials’ option in the menu, finding the trial you wish to know more about and filling out the form on that page.

If you have not received a reply within 3 working days please email gina.brown@rmh.nhs.uk

Blog

This is the page where users will find your site’s blog